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Malignant peripheral nerve sheath tumor (MPNST) is a rare subtype of soft tissue sarcoma. 
Surgical excision has remained the standard of care for this highly aggressive malignancy for 
over a decade. Conventional chemotherapy and radiotherapy have shown limited efficacy in 
MPNST; therefore, it is imperative that targeted treatment be identified to improve the outcome 
for MPNST patients. Poly (ADP) ribose polymerase (PARP) inhibitors were first reported over 
a decade ago to have substantial anti-tumorigenic effects in malignancies with defective DNA 
repair, specifically those with BRCA1/2 (breast cancer, early onset 1/2) mutations. Further 
evaluation of these inhibitors has shown multiple mechanisms of sensitivity, all of which are 
associated with the DNA damage response and DNA repair. While no specific defects in DNA 
repair machinery have been reported in MPNST, sensitivity to PARP inhibition may be 
predicted by its complex karyotype and inherent genomic instability. We show increased 
PARP1 and PARP2 expression in MPNST patient tumor samples and increased PARP activity 
in cell lines. We also demonstrate the anti-MPNST effect of the PARP inhibitor AZD2281 in 
vitro and in vivo. Specifically, decreased cell proliferation and induction of apoptosis were 
observed in MPNST cell lines at AZD2281 doses and time points similar to, or less than, those 
used in cells lines with known DNA repair defects. In addition, AZD2281 treatment suppressed 
MPNST subcutaneous xenograft growth and lung metastasis progression, and increased 
survival times of mice with metastatic disease. Upon investigation of a potential mechanism of 
sensitivity, we found decreased efficacy of homologous recombination (HR) and increased 
vii 
 
activity of non-homologous end joining (NHEJ) in MPNST cell lines, suggesting a potential 
mechanism of sensitivity to PARP inhibition due to increased genomic instability. We also 
observed decreased expression of Cockayne syndrome B (CSB), a pivotal member of the 
transcription coupled repair (TCR) pathway. Subsequent overexpression of CSB decreased 
the sensitivity of a subset of MPNST cell lines to AZD2281 treatment. Our results suggest that 
PARP is a valuable anti-MPNST target and that sensitivity could be due to defective DNA repair 
pathways. Moreover, AZD2281 should be evaluated for its efficacy as a therapeutic agent for 
MPNST patients.   
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 Chapter 1  
Introduction 
 
1.1 Soft tissue sarcoma 
 Soft tissue sarcoma (STS) is a relatively rare malignancy, accounting for less than 1% 
of adult cancers diagnosed in 2015. (1) These tumors can arise in muscle, fat, blood 
vessels, and nerves and occur in any area of the body, with the majority arising in the 
extremities. (2) There are over 80 distinct histological subtypes of STS which are classified 
and named according to their cell of origin. (3) While the incidence of STS is rare with 
approximately 12,000 new cases diagnosed in the United States annually, 41% of patients 
are expected to succumb to their disease. (1) Overall, the five-year survival rate for STS is 
83% for localized disease and substantially decreases with more advanced disease to 16% 
for patients with distant spread. (1)  
 STS can be categorized into two groups based on the type and extent of the molecular 
alterations characteristic of histological subtypes. Several STSs, such as Ewing’s sarcoma, 
well-differentiated liposarcoma, have a “simple karyotype”, with defined recurring 
chromosomal translocations and copy number changes that are linked to tumorigenesis. 
(4) Within this category are also those STSs with specific genetic mutations that drive tumor 
formation such as the v-kit hardy-zuckerman 4 feline sarcoma viral oncogene (cKIT) or 
platelet-derived growth factor receptor, beta polypeptide (PDGFRB) mutation in 
gastrointestinal stromal tumor. (5) However, the majority of STSs has complex karyotypes 
associated with substantial chromosomal aberrations and high levels of genomic instability. 
(6) One example of a karyotypically complex STS is malignant peripheral nerve sheath 
tumor (MPNST). 
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1.2 Malignant peripheral nerve sheath tumor 
Incidence and clinical features 
MPNST accounts for 2-5% of all STS diagnoses, accounting for approximately 238 
new cases in the United States annually (Figure 1). (3,7) MPNST can arise in three settings: 
sporadic, neurofibromatosis type 1-associated (NF1-associated), and radiation-associated. 
Sporadic MPNST accounts for 40% of cases, while NF1-associated MPNST accounts for 
50% of cases. Radiation-associated MPNST occurs in a field of prior therapeutic radiation 
and accounts for 10% of cases. (7-9) 
 
Figure 1. Soft tissue sarcoma subtypes. Distribution by histology for adult patients with 
soft tissue sarcoma, all sites. MSKCC 7/1/1982-6/30/2010. GIST: gastrointestinal stromal 
tumor; UPS: undifferentiated pleomorphic sarcoma; MPNST: malignant peripheral nerve 
sheath tumor  
Reprinted with permission from Springer New York (3), copyright 2013. 
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In general, MPNST is a highly aggressive tumor that often occurs in the upper or lower 
extremities involving large nerve bundles such as the sciatic nerve or the brachial plexus. 
(7) Due to the rapidly growing nature of the disease, patients will present with pain, motor 
weakness, or paresthesia; additionally, up to 50% of patients will present with systemic 
disease. (7)  
Neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor 
Neurofibromatosis type 1 (NF1) is the most common hereditary disease affecting 
approximately 1 in 3000 individuals. NF1 is typified by several clinical features, most 
commonly café-au-lait spots, skinfold freckling, cognitive impairment, and cutaneous 
neurofibromas (Figure 2). (10) In NF1 patients, a mutation of one allele of the neurofibromin 
1 (NF1) gene is inherited in an autosomal dominant fashion, or occurs de novo, and is 
defective in all cells, resulting in a loss of heterozygosity. A second acquired mutation then 
occurs in Schwann cells resulting in the formation of neurofibromas. According to the 
human gene mutation database, almost 1500 mutations of NF1 have been reported and 
are associated with the disease phenotype. Approximately 5-10% of NF1 patients will have 
a large deletion of NF1 accompanied by a deletion in the surrounding chromosomal area, 
which is associated with a severe phenotype; or microdeletions either 1.4Mb in size 
encompassing 14 genes or 1.3Mb in size encompassing 13 genes. (11) However, the 
majority of patients (approximately 90%) will have a NF1 intragenic mutation, where no 
clear phenotype-genotype correlation has been established. (11,12)  
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Figure 2. Clinical manifestations of neurofibromatosis type I (NF1).  
Reprinted with permission from the neurofibromatosis network.  
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Neurofibromas manifest as superficial cutaneous neurofibromas (localized nodules 
on or beneath the skin found in almost all adult NF1 patients) and/or as diffuse or plexiform 
neurofibromas (deep-seated tumors that growth along the length of large nerve bundles 
which occur in approximately 30-40% of patients). (13) Only deep neurofibromas can 
undergo malignant transformation to become MPNSTs, which is the main cause of 
morbidity and mortality of NF1 patients. (14) Malignant transformation in NF1 patients 
peaks at adolescence with an increased risk remaining through adulthood. (15) There is an 
estimated 8–13% lifetime risk of MPNST development in NF1 patients (Figure 3). (13) 
 
Figure 3. Neurofibromatosis type I molecular pathogenesis. Neurofibromatosis 1 (NF1) 
is a neurogenetic disorder caused by loss of function of the NF1 gene. Neurofibromas are 
the most common benign peripheral nerve sheath lesions in NF1 and manifest as superficial 
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cutaneous neurofibromas (nonplexiform) in virtually all patients and/or as deep (often 
plexiform) neurofibromas. Only deep neurofibromas have the significant propensity to 
undergo malignant transformation to MPNSTs, with an estimated 8–13% lifetime risk in a 
patient. Most MPNSTs are believed to arise in association with deep neurofibromas, but 
they may arise outside of this context as well. In the superficial cutaneous neurofibroma 
panel, a clinical photograph depicts a cutaneous neurofibroma (red arrow), and a 
radiograph from a different patient shows both superficial (red arrow) and deep (blue arrow) 
neurofibromas involving the lower extremity. The haematoxylin and eosin (H&E) 
photomicrograph shows a dermal neurofibroma. The deep neurofibroma panel features a 
radiograph of lobular, plexiform neurofibroma (red arrow) deep in the pelvis and an H&E 
image of a plexiform neurofibroma associated with a nerve (blue arrow). Additional 
molecular events must accumulate for malignant transformation. In the MPNST panel, an 
intraoperative photograph shows an MPNST in an NF1 patient involving the sciatic nerve 
with a histological photomicrograph of an MPNST below. The images to the right show a 
radiograph of an MPNST near the scapula and a PET (positron emission tomography) 
image showing avid glucose uptake consistent with intense metabolic activity in the same 
case directly below. Clinical and radiographic images were kindly provided by John 
Madewell, John Slopis and Ian McCutcheon of M.D. Anderson Cancer Center, Houston, 
TX, USA. Abbreviations: LOH, loss of heterozygosity; MPNST, malignant peripheral nerve 
sheath tumour; NF1, neurofibromin gene.  
Reprinted with permission from Cambridge University Press: [Expert Reviews in Molecular 
Medicine] (13), copyright 2009.   
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Molecular characteristics 
The NF1 gene encodes the protein neurofibromin which functions as a Ras GTPase-
activating protein, a key negative regulator of the mitogen-activated protein kinase (MAPK) 
pathway. Mutated NF1 effects the expression and/or function of neurofibromin. Loss of 
neurofibromin function results in dysregulated Ras activity and hyperactive MAPK signaling, 
leading to constitutive activation of downstream pathways and increased cell proliferation. 
(10) Association with a genetic cancer predisposition disorder makes MPNST unique from 
other STS subtypes. 
Available treatment options 
MPNST is largely unresponsive to chemotherapy or radiotherapy; however, 
neoadjuvant chemotherapy has been shown to provide disease stabilization, and external 
beam radiation therapy may offer improved local control. (16) Therefore, the mainstay of 
treatment for MPNST is surgical resection, though this is often difficult due to the location 
and size of these tumors. (17,18) Recent studies have identified several recurring genetics 
aberrations in MPNST (occurring in NF1, TP53, CDKN1B, PDGFRA, HGF, and others), as 
well as irregular receptor tyrosine kinase activity that could be exploited for treatment or 
highlight other targetable molecular dysregulations. (19-21) However, clinical trials 
evaluating targeted agents such as erlotinib (targeting EGFR), sorafenib (targeting VEGF 
and RAS), and imatinib (targeting KIT) reported minimal observed responses in STS 
patients, including those with MPNST. (7,22)  
Patient outcome 
Even with surgical resection of primary disease, studies show MPNSTs have a high 
propensity to recur (40%-65%) and metastasize (41%). (13,23) Metastasis typically occurs 
to the lung (67%) with the liver and brain being less common sites (36%). (23) Additionally, 
in the MD Anderson Cancer Center experience with MPNST cases, the five-year survival 
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rate for patients with NF1-associated MPNST is approximately 48%. The five-year survival 
rate decreases substantially in patients with radiation-associated MPNST (43%), while 
increasing slightly in patients with sporadic MPNST (63%) (Figure 4). (24) 
 
 
Figure 4. Disease-specific survival of MPNST patients by etiology.  
Reprinted from Watson, K. L., Al Sannaa, G. A., Kivlin, C. M., Ingram, D. R., Landers, S. 
M., Roland, C. L., Cormier, J. N., Hunt, K. K., Feig, B. W., Guadagnolo, B. A., Bishop, A. 
J., Wang, W.-L., Slopis, J. M., McCutcheon, I. E., Lazar, A. J. & Torres, K. E. Patterns of 
recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-
associated malignant peripheral nerve sheath tumors (MPNSTs). Journal of Neurosurgery, 
In Press. (2016). (24) 
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1.3 Poly (ADP) ribose polymerases 
Family members and function in DNA repair  
Poly (ADP) ribose polymerases (PARP) were first identified in 1966 with the discovery 
of PARP1. (25) Subsequent PARPs were characterized based on their sequence homology 
to the PARP domain/catalytic domain in PARP1, resulting in a PARP superfamily with 17 
members, named sequentially PARP1- PARP 16. (26) PARPs contain several conserved 
domains: domain A is a deoxyribonucleic acid (DNA) binding domain containing two zinc 
fingers, domain B contains a nuclear localization sequence, domain D is an 
automodification domain, and domain F is the catalytic domain. (27,28) The enzymatic 
product of PARP is poly (ADP) ribose (PAR) which acts to post-translationally modify 
nuclear acceptor proteins. (28) Enzymatic activity has mainly been attributed to PARP1 
(>90%) and PARP2 (5-10%). (25,29) 
Upon stimulation by DNA single strand breaks, PARP catalytic activity increases 
approximately 500 fold and, via its DNA binding domain, binds to sites of DNA damage. (25) 
Using the ADP ribosyl moiety of NAD as a substrate, PARP generates long, often branched, 
chains of PAR of various sizes in successive transfer cycles onto nuclear acceptor proteins 
with the release of nicotinamide. (28) Poly (ADP) ribosylation (PARylation) domains 
frequently overlap with the functional domains of acceptor proteins, thereby altering their 
function. (30) Additionally, PAR is highly negatively charged, therefore PAR can also alter its 
acceptor protein’s functions, including protein-protein interactions, protein-nucleic acid 
interactions, enzymatic activity, and/or subcellular localization, via charge effects or by acting 
as a steric block due to its large size. (31) This is a well-balanced process which leads to a 
rapid turnover of PAR. Poly (ADP) ribose glycohydrolase (PARG) splits the ribose-ribose 
linkages of PAR, creating free ADP-ribose and de-PARylating the acceptor protein (Figure 5). 
(28) 
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Figure 5. Poly (ADP) ribose polymerase function. Poly (ADP- ribose) polymerases 
(PARPs) use the ADP-ribosyl moiety (L- shaped symbols in blue) for NAD+ to covalently 
modify acceptor proteins in successive transfer cycles thus creating branched chains of poly 
(ADP-ribose), with stoichiometric release of nicotinamide. Poly (ADP-ribose) glycohydrolase 
(PARG) splits the ribose- ribose linkages between ADP- ribosyl units of the polymer, thus 
creating free ADP- ribose.  
Modified and reprinted with permission from John Wiley and Sons: [Bioessays] (28), 
Copyright 2001.  
 
 
 
11 
 
The classic role of PARP is in DNA damage repair through the base excision repair 
(BER) pathway. Upon single strand DNA damage, PARP signals the extent of injury and 
relaxes the chromatin, by PARylating histones, for increased access to DNA breaks; 
additionally, a large portion of PAR is bound to PARP itself in an automodification reaction. 
PARP activity recruits other repair proteins either directly by PARylation or indirectly 
through interaction with other PARylated proteins, such as the scaffold protein x-ray repair 
complementing defective repair in Chinese hamster cells 1 (XRCC1), that assemble and 
activate BER. PARylation of PARP1 causes its release from damaged DNA which 
suppresses further PAR synthesis and provides access for other repair proteins to fully 
repair the DNA insult (Figure 6). (32,33) The BER process begins with the recognition and 
removal of the damaged base by DNA glycosylase, which creates an abasic site (AP site). 
(34) The DNA backbone is then cut on the 5’ side by an AP endonuclease, such as apurinic-
apyrimidinic endonuclease 1 (APEX1), which is subsequently removed by a DNA 
phosphodiesterase. DNA polymerase 1 then replaces the missing base alone (short patch 
BER) or along with several bases downstream by first removing them with its 5’ to 3’ 
exonuclease activity, then replacing them with its polymerase activity (long patch BER). 
(35-37) Long patch BER also requires the activities of PCNA to assist DNA polymerase in 
displacement and synthesis of DNA longer than one base. (37) This process creates a flap 
that is incompatible with ligation. (37) Therefore, flap endonuclease 1 cleaves the resulting 
flap so the gaps can be ligated. (37) DNA ligase 3 (short patch BER) or DNA ligase 1 (long 
patch BER) completes the repair by annealing the gap. (34,36) PARP1 has been shown to 
be able to bind to approximately 90% of genes transcribed by RNA polymerase II; 
additionally PARP2 is a positive cofactor for transcription of approximately 600-1000 genes. 
(33) PARylation acceptor proteins also include those involved in transcription, replication, 
cell cycle, chromatin structure, and cell death, therefore PARPs have non-DNA damage 
function as well. (38) 
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Figure 6. Effect of Poly (ADP) Ribose Polymerase function and inhibition on DNA 
repair. PARP is activated in response to DNA SSB by detecting and binding SSB to initiate 
the process of BER. Its catalytic activity results in poly(ADP-ribosyl)ation on itself and other 
key BER proteins such as XRCC1. Activated PARP then recruits other DNA repair proteins 
via poly(ADP-ribosyl)ation and direct interactions to facilitate DNA repair. The cellular levels 
of PAR are regulated by the opposing actions of PARP and PARG. Degradation of PAR 
polymer by PARG leads to release of modified proteins from damaged DNA. PARP 
inhibition causes an increase in persistent SSBs in DNA that are converted into DSBs. Both 
HR and DDR proteins are involved in the repair of DSBs. However, HR deficient cells or 
cells with BRCAness are unable to repair the accumulated DSBs caused by PARP 
inhibition, resulting in collapsed replication forks, chromosome instability and cell death. 
Reprinted from Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP 
inhibitor therapies. American Journal of Cancer Research. 2011;1(3):301-327. (32) 
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Poly (ADP) ribose polymerase inhibition 
Nicotinamide was the first PARP inhibitor to be established and was evaluated almost 
thirty years ago. (39) Second generation PARP inhibitors were then discovered through 
screening of chemical libraries, thus enhancing the potency and structure-specific activity of 
these inhibitors. (40) The current third generation inhibitors act as a competitive inhibitor of 
NAD, the substrate of PAR. (41,42)  
There are two approaches for the clinical development of PARP inhibitors: (1) exploit a 
defect in the targeted cell so the cell dies when PARP activity is lost (synthetic lethality) or (2) 
use a PARP inhibitor as a chemosensitizer, in combination with traditional chemotherapy or 
radiotherapy. Synthetic lethality is the principle that either of two mutations has no effect, but 
the combination of mutations is lethal. This idea was applied to cancer therapeutics in 1997. 
(43) For example, the addition of a PARP inhibitor would compromise the efficacy of BER and 
lead to the conversion of single strand breaks to double strand breaks. If the cell has intact 
DNA double strand break repair machinery, the damage can be repaired and the cell would 
survive. However, if PARP inhibition is applied to a cell with a deficiency in homologous 
recombination (HR), the error-free pathway of DNA double strand break (DSB) repair, the cell 
will be unable to fix the damage and the replication fork will collapse, leading to chromosomal 
instability and cell death due to mitotic catastrophe (Figure 6). (32,44)  
Most notably, PARP inhibition in tumors with a breast cancer 1/2, early onset (BRCA1/2) 
mutation or a BRCA-deficient phenotype without a germline BRCA mutation (termed 
“BRCAness”) was shown to cause synthetic lethality. (45,46) The majority of preclinical and 
subsequent clinical studies with PARP inhibitors have been performed in BRCA-mutated 
breast and ovarian carcinomas with significant anti-tumor effects reported. (47) Over 100 
clinical trials have been performed with an array of PARP inhibitors alone and in combination 
with conventional chemotherapies.  
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The PARP inhibitor AZD2281 (Olarparib) is arguably the most well-characterized PARP 
inhibitor clinically available, and has been shown to have significant single-agent efficacy in 
BRCA-mutant cells and synergizes with DNA-damaging platinum drugs in preclinical studies. 
(48,49) In clinical trials, AZD2281 has been shown to be generally well-tolerated and 
produced an objective response in 47% of 19 patients with BRCA-mutant breast, ovarian, or 
prostate cancer, in addition to a 63% disease control rate. (50,51) Currently, AZD2281 is in 
several phase 3 clinical trials including study of olaparib in ovarian cancer (SOLO1 and 
SOLO2) for BRCA-mutated ovarian cancer. 
However, recent studies have revealed that due to the nature of BRCA mutations, drug-
resistant populations can form, due to secondary mutations that restore wildtype function of 
BRCA, increased expression and function of hypomorphic BRCA1/2, or increased drug efflux. 
(52) Because this population seems to develop over a period of time, a heterogeneous tumor 
population may exist prior to treatment. Continued exposure to a PARP inhibitor results in the 
selection of the drug resistant population, which becomes the predominate population, 
therefore PARP inhibition is no longer an effective therapy. (52) 
Almost ten years ago, studies showed that cancer cells with defective DNA repair 
proteins such as ataxia telangiectasia and Rad3 related (ATR), ataxia telangiectasia mutated 
(ATM), and checkpoint kinase 1/2 (CHK1/2) are profoundly sensitive to PARP inhibitors and 
may represent biomarkers for patient selection and PARP efficacy. (46,53) In addition, the 
presence of the EWS-FLI1 fusion protein, resulting from the EWS RNA-binding protein 1-Fli-
1 proto-oncogene, ETS transcription factor translocation in Ewing’s sarcoma, has been 
shown to elicit PARP inhibitor sensitivity. (54) This preclinical observation has led to a current 
clinical trial for Ewing’s sarcoma patients that have failed traditional chemotherapies. Lord 
and Ashworth have also proposed other predictive biomarkers of PARP inhibitor sensitivity 
including loss of function mutations of cyclin-dependent kinase 12 (CDK12), often found in 
serous ovarian cancer, and loss of expression of excision repair cross-complementation 
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group 1 (ERCC1), seen in non-small cell lung cancer. (51) These findings expand the use of 
PARP inhibitors beyond BRCA-mutant cancer types and could lead to larger clinical trials 
where patients are included based on genetic screenings of their tumors.  
1.4 Nucleotide excision repair  
Function in DNA repair 
The nucleotide excision repair (NER) pathway repairs bulky DNA lesions that cause 
a distortion of the DNA; the two major types of photoproducts that result in this type of 
distortion are cyclobutane pyrimidine dimers (CPDs) and [6,4]-pyrimidine dimers. (55,56) 
This type of DNA adduct can be caused by exogenous (UV) or endogenous (reactive 
oxygen species) sources. (57) The pathway is divided into two sub-pathways: repair of the 
actively transcribed pathway (transcription coupled repair), and the non-transcribed region 
(global genome repair). (58) During transcription coupled repair (TCR), DNA damage is 
detected through the arrest of RNA polymerase. (59) Cockayne syndrome A and B then 
allow access to the DNA damage site by inducing dissociation of RNA polymerase as well 
as recruiting several TCR-specific proteins involved in chromatin remodeling for rapid repair 
of the lesion, including UV-stimulated scaffold protein A (UVSSA), ubiquitin-specific-
processing protease 7 (USP7), XPA-binding protein 2 (XAB2), high mobility group 
nucleosome-binding domain-containing protein 1 (HMGN1), and the transcriptional 
elongation factor, TFIIS. (60,61) These factors help to facilitate chromatin remodeling and 
enable the resumption of transcription after the lesion is removed. (62) DNA damage in 
global genome repair is detected through the binding of xeroderma pigmentosum, 
complementation group C (XPC) (further stabilized by human homolog of RAD23B 
(HHRAD23B) and centrin 2 (CETN2)), and XPE which serves to further stimulate XPC 
binding to the lesion, and is thought to further distort the DNA structure. (61) Subsequent 
steps of DNA repair are identical between the two sub- pathways. (63) The general 
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transcription factor complex (TFIIH) binds the area of DNA damage through the interaction 
with either XPC or the arrested transcription machinery. (63) This complex is composed of 
ten subunits, most notably xeroderma pigmentosum, complementation group B (XPB) and 
xeroderma pigmentosum complementary group D (XPD). XPB and XPD are DNA helicases 
which unwind DNA from 5’ to 3’ or 3’ to 5’ respectively, near the damaged base. XPD also 
acts as a verification step and checks for distortion of the DNA strand, as well as, a 
damaged base to prevent unnecessary NER. (59,63) Once the DNA is unwound, replication 
protein A (RPA) is recruited and acts to protect the separated single strand. (60) Xeroderma 
pigmentosum, complementation group G (XPG), a structure specific nuclease, is also 
recruited at this time, whereas XPC is released, free to recognize other damaged sites to 
initiate a new round of NER. (64) The area around the damage is then cleaved by 
XPG/XPA, a 3’ nuclease, and a 5’ nuclease, xeroderma pigmentosum, complementation 
group F-excision repair cross-complementation group 1 (XPF-ERCC1). (60,65) The region 
containing the lesion is displaced, allowing for gap repair synthesis. DNA polymerase delta 
(along with replication factor C (RFC), and proliferating cell nuclear antigen (PCNA)), or 
DNA polymerase epsilon alone bind to the 3’-OH overhang created by the cut of XPF-
ERCC1 and extend the DNA to span the gap, thus causing the displacement of the repair 
proteins. (59,65) The gap is finally ligated by DNA ligase I or by DNA ligase III in non-cycling 
cells (Figure 7). (58,61)  
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Figure 7. Nucleotide excision repair. The nucleotide excision repair (NER) system 
consists of a series of reactions by which DNA damage caused by, for example, ultraviolet 
radiation-induced photoproducts or similar chemically induced products is recognized and 
repaired. Damage can occur from external and endogenous sources (shown as a balance 
in the figure). Photoproducts include cyclobutane pyrimidine dimers (CPDs) and [6–4] 
photoproducts, which can both involve T and C pyrimidines. When repair of these photo- or 
chemical products is faulty owing to mutations in the NER system, replication errors lead to 
characteristic C to T mutations, especially CC to TT mutations, which are found in TP53, 
Patched 1 (PTCH1) and other oncogenes in sunlight-induced skin cancers of patients with 
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xeroderma- pigmentosum (XP) and others. The damage is endogenous in other systemic 
disorders and is thought to be caused mainly by reactive oxygen species (ROS). Depending 
on whether the damage occurs in a transcriptionally active or inactive domain, repair can 
occur by two pathways: global genomic repair (GGR) or transcription-coupled repair (TCR) 
(shown in the figure). Damage in transcriptionally active regions is detected through the 
arrest of transcription by RNA polymerase I (RNAPI; not shown) and RNA polymerase II 
(RNAPII). Transcription arrest is enhanced by mutations in the Cockayne syndrome A 
(CSA) and Cockayne syndrome B (CSB) proteins, and both are required for ubiquitylation 
of the carboxy-terminal domain of RNAPII. Cells with mutations in CSA (also known as 
ERCC8) and CSB (also known as ERCC6) do not show the increased rate of photoproduct 
repair in transcriptionally active regions that occurs in normal cells, and carry out GGR at 
normal rates. Arrested polyubiquitylated RNAPII is removed and degraded, leaving the 
active genes accessible for repair and the resumption of transcription. CSA is a WD40 
protein that is part of the ubiquitin E3 ligase that acts on XPC and DNA damage-binding 2 
(DDB2). Damage in transcriptionally inactive regions is detected by the DNA 
damage-binding protein XPC and complex Damage-Specific DNA Binding Protein 1 (XPE). 
Mutation of either of these can cause XP140. The individual DNA damage-binding proteins 
have weak affinities for their substrate, so the binding process can be viewed either as a 
sequential process in which one protein facilitates binding by another or as a grouping of 
weakly interacting partners that form transient pre-incision complexes that are locked in 
place by the XPB (also known as ERCC3) ATPase. The CPDs and [6–4] photoproducts 
make substantially different structural changes in DNA: CPDs are much less distorting and 
require more active participation of XPE. Damage recognition is followed by binding of the 
ten-component basal transcription factor TFIIH through interaction with either XPC or the 
arrested transcription apparatus. XPD (also known as ERCC2) is a component of TFIIH 
and is a DNA helicase that is involved in 5′ to 3′ unwinding of the DNA in the vicinity of a 
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damaged base. ATP hydrolysis by the XPB component of TFIIH facilitates binding of the 
NER complex to the damaged site. The amino terminus of XPB interacts with XPD and 
XPG (also known as ERCC5), whereas the carboxyl terminus is required for 5′ cleavage. 
XPD carries out a further damage recognition step when its migration along the helix is 
blocked by a photoproduct. The DNA around the damaged site is then cleaved by the XPG 
3′ nuclease and the XPF–ERCC1 5′ nuclease. Recent evidence suggests that 5′ cleavage 
occurs first. XPG is bound through interaction with XPC and TFIIH. The nucleases are 
anchored by XPA–replication protein A (RPA), which defines the cleavage sites and strand 
specificity. Once the damaged oligonucleotide is removed, a patch is resynthesized by 
proliferating cell nuclear antigen, polymerases δ, ε or κ and a ligase. In quiescent cells, 
ligation involves X-ray repair cross-complementing protein 1 (XRCC1) and ligase III. In 
proliferating cells, ligation involves ligase I. 
Reprinted with permission from Nature Publishing Group: [Nature Reviews Genetics] (66), 
copyright 2009.  
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Mutations within the NER pathway can give rise to xeroderma pigmentosum (XP), 
caused by a mutation in XP (subtype A-G) genes, Cockayne syndrome (CS), caused by a 
mutation in ERCC6/8, or trichothiodystrophy, caused by a mutation in ERCC2/3. (65) Cells 
with a mutation in CSA or CSB do not show the increased rate of DNA repair in the 
transcriptionally active strand due to a loss of TCR, instead those cell carry out GGR at 
normal rates. (57,66) CS patients have light sensitivity, neurological, facial, and limb 
abnormalities, premature aging, dwarfism, and often early death due to neurodegeneration. 
(57,63,66) If the NER pathway is deficient, the replication fork may collapse and the single 
strand breaks can be converted into double strand DNA breaks. (67,68)     
Possible implication with poly (ADP) ribose polymerase inhibitors 
In addition to BRCAness, other components of DNA repair may determine sensitivity to 
PARP inhibition. Lord and Ashworth demonstrated, via siRNA screen, that the nucleotide 
excision repair genes, XPA binding protein (XAB2) and damage-specific DNA binding protein 
(DDB1), were lethal targets when combined with PARP siRNA. (69) The authors 
hypothesized that TCR-deficient cells may stall the replication fork in response to DNA 
lesions, leading to cell cycle arrest until the fork can be restarted. This can lead to collapse of 
the replication fork and double strand DNA breaks beyond a threshold that is compatible with 
cell viability. Therefore a TCR deficiency can make cells sensitive to PARP inhibition.   
1.5 Double strand DNA repair mechanisms 
Homologous Recombination 
Double strand DNA breaks are the most detrimental form of DNA damage. (70) 
Double strand DNA breaks can occur through multiple physical (ex: replication across a 
nick) or pathological (ex: ionizing radiation) means. (71) There are two main methods of 
double strand DNA break repair: homologous recombination (HR) and non-homologous 
end joining (NHEJ). HR is a high fidelity pathway that requires a homologous region of DNA 
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as a template to repair the damage and therefore occurs during S and G2 phases of the 
cell cycle. (70,72,73) HR is initiated when the meiotic recombination 11/ RAD50 homolog/ 
Nijmegen breakage syndrome 1 (MRE11/Rad50/NBS1 [MRN]) complex and CtBP 
interacting protein (CtIP) are recruited to sites of double strand DNA damage. (73) This 
leads to 5’ to 3’ end resection of the DNA by MRN and further resection by exonuclease 1 
(EXO1) to produce long stretches of 3’ single strand DNA, which is then coated by 
replication protein A (RPA) to prevent the formation of secondary structure. (58,73,74) 
Resection of the DNA ends commits the repair of the DSB to the HR pathway as opposed 
to NHEJ and is facilitated by BRCA1. (75,76) BRCA2, in a relatively not-well understood 
process, interacts with BRCA1, BRCA1 associated RING domain 1 (BARD1), and partner 
and localizer of BRCA2 (PALB2) to displace RPA, and enable the loading of 
RAD51 recombinase (Rad51) onto the 3’ overhangs. (58,73,74,77) The Rad51-DNA 
filaments, referred to as the nucleofilament, further stabilized by Rad54 then invade the 
sister chromatid in search of a homologous sequence and form the synaptic complex, a 
three strand intermediate that allows the invading strand to anneal with the complementary 
strand and displace the third strand to form a structure known as the D loop. (58,72,74,78) 
The 3’ end of the invading strand is then extended by DNA polymerases, in a process called 
strand extension. (73) If this newly synthesized strand dissociates from the template strand 
and reanneals with the other original ssDNA overhang, it will form a non-crossover product 
in a process termed synthesis-dependent strand annealing (SDSA). (72,74) Evidence 
suggests this is the main conclusion of DNA DSBs in somatic mammalian cells. (79) 
Otherwise the extension of the invading strand can cause the D loop to migrate until it 
reaches the second end of the double strand break where it can form two Holliday junctions 
(HJs), in a process called second end capture. (72) The bloom syndrome, recQ helicase-
like-topoisomerase III-recQ mediated genome instability 1 (BLM-TOPOIII-RMI1) complex 
can then resolve the Holliday junctions to a non-crossover product. (58,72,74) Alternatively, 
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the Holliday junctions can be ameliorated by HJ resolvases such as MUS81 structure-
specific endonuclease subunit- essential meiotic structure-specific endonuclease 1 
(MUS81-EME1), GEN1 (Holliday junction 5' flap endonuclease), or SLX1 structure-specific 
endonuclease (SLX1-SLX4), which can lead to crossover or non-crossover products due 
to their symmetrical cleavage of the Holliday junctions (Figure 8). (58,74) 
 
Figure 8. Homologous Recombination (HR). After DNA damage end resection by MRN 
and CtIP, PALB2–BRCA2 activates RAD51 to promote the invasion of an undamaged 
template, leading to synthesis-dependent strand annealing or second-end capture and 
double–Holliday junction formation to allow DSB repair.  
Reprinted with permission from Nature Publishing Group: [Nature Structural and Molecular 
Biology] (77), Copyright 2010.  
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Implication with PARP inhibitors 
PARP inhibitors are primarily used in malignancies with a deficiency in homologous 
recombination (HR) in order to enhance the conversion of single strand DNA breaks to 
double strand DNA breaks. The inability of the HR deficient cell to efficiently repair double 
strand DNA breaks translates into replication fork collapse and cell death. (80) However, 
there are currently no publications citing a homologous recombination pathway deficiency 
in MPNST. 
Non-Homologous End Joining  
Determining whether double strand DNA breaks will be repaired by HR or NHEJ is a 
complex question. If the damage occurs outside of the S or G2 phase where a sister 
chromatid or homologous chromosome is not available, HR cannot occur and NHEJ must 
be used to repair the damage. (71,73) In addition, tumor protein p53 binding protein 1 
(53BP1) and its effector replication timing regulatory factor 1 (Rif1) act to antagonize 
BRCA1 and direct repair through NHEJ. (76) Upon DNA damage, the Ku autoantigen p70 
subunit/Ku autoantigen p80 subunit (Ku70/Ku80) heterodimer binds to each side of the 
double strand break and prevents non-specific 5’ end resection. (74,81) This protein has a 
high affinity for DNA ends and is ubiquitously expressed in the cell (approximately 500,000 
molecules per cell); once bound it is referred to as a Ku:DNA complex. (71,74,81) These 
end complexes can recruit subsequent nuclease, polymerase, and ligase proteins in any 
order, causing a large number of outcomes that can possibly result from the same starting 
lesion in NHEJ. (58,82) DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is 
recruited to the Ku:DNA complex and forms the DNA-PK holoenzyme. Artemis is recruited, 
phosphorylated, and therefore activated by DNA-PKcs, where it processes incompatible 
DNA ends due to its diverse nuclease activity. (82) DNA-PKcs also acts to tether the two 
ends of the DNA together, as well as protect the ends from degradation and prevent 
premature ligation. (58,70) If the DSB is highly complex, polymerase mu and lambda are 
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recruited by the Ku:DNA complex to synthesize and fill the gap. (71,73) Polymerase mu is 
highly adaptable, able to perform template-dependent synthesis but can also polymerize 
across a discontinuous template strand, making it well-suited for this flexible DNA repair 
mechanism. (81) Polymerase lambda has also been shown to have template-independent 
activity. (81) Finally, x-ray cross-complementation group 4 (XRCC4), nonhomologous end-
joining factor 1 (NHEJ1), also known as XRCC4-like factor (XLF) and DNA ligase 4 seal the 
ends. (58,73,83) Compared to HR, NHEJ is a highly error-prone process and its resulting 
DNA product are highly mutagenic and inaccurate compared to the original sequence. 
(71,83,84) If the DNA ends have at least four nucleotides of sequence homology on DNA 
overhangs, XRCC4-DNA ligase 4 can simply ligate the ends of one single strand overhang 
while the other is filled by polymerases, without the activity of any of the members of the 
NHEJ pathway. (71,82) This scenario is the only form of NHEJ in which the original 
sequence of the DNA could be preserved (Figure 9). (71,82). 
 
25 
 
 
Figure 9. Non- Homologous End Joining (NHEJ). There are two main pathways of DNA 
repair: NHEJ and homologous recombination. A, NHEJ. a, A DSB is recognized by the Ku 
dimer (Ku70–Ku80) and DNA-PKcs. b, The two DNA ends are synapsed. c,DNA-PKcs and 
Artemis are phosphorylated, and the DNA ends are processed by a complex consisting of 
XLF (XRCC4-like complex; also known as NHEJ1), XRCC4 (X-ray-repair cross-
complementing protein 4) and DNA ligase IV, and by Artemis. d, The DNA ends are ligated 
by DNA ligase IV, and the DNA-repair factors dissociate.  
Modified and reprinted with permission from Nature Publishing Group: [Nature] (85), 
Copyright 2007.  
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Possible implication with PARP inhibitors 
It has been shown recently that treatment with a PARP inhibitor enhanced the 
phosphorylation of DNK-PKcs and therefore aberrantly activate NHEJ in ovarian cancer cell 
lines. (86) The authors of this study hypothesize that the deregulated and highly mutagenic 
NHEJ further increases genomic instability and cytotoxicity associated with PARP inhibition. 
Therefore, in the setting of HR- deficiency, increased NHEJ activity contributes to synthetic 
lethality and may predict sensitivity to PARP inhibitors (Figure 10).  
 
Figure 10. Role of HR and NHEJ in PARP inhibition. Current model explaining synthetic 
lethality of PARP inhibition and HR deficiency. PARP inhibition is thought to induce 
accumulation of SSBs, which are converted to DSBs by collisions with replication 
machinery. The inability of HR-deficient cells to adequately repair DSBs results in genomic 
instability and eventual cell death. 
Reprinted from Patel, A. G., Sarkaria, J. N. & Kaufmann, S. H. Nonhomologous end joining 
drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-
deficient cells. Proceedings of the National Academy of Sciences of the United States of 
America 108, 3406-3411, doi:10.1073/pnas.1013715108 (2011). (86) 
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1.6 Hypothesis and specific aims 
Although MPNSTs do not have a characterized defect in BRCA1/2 or any DNA repair 
pathway deficiency, they have a karyotypically-complex phenotype that would suggest a 
deficiency in DNA damage repair and a high level of inherent DNA damage and genomic 
instability. (87,88) Therefore, I hypothesize that poly (ADP) ribose polymerase (PARP) 
inhibition is an effective therapeutic strategy in MPNST.  
To pursue this hypothesis, I developed the following specific aims: 
 
Aim 1: Evaluate the effects of PARP inhibition on MPNST in vitro and in vivo.  
 
Aim 2: Identify potential mechanisms underlying MPNST sensitivity to PARP 
inhibitors. 
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Chapter 2 
Materials and Methods 
Clinically annotated tissue microarray 
This study was approved by The University of Texas MD Anderson Cancer Center 
Institutional Review Board. A clinically annotated tissue microarray (TMA) containing samples 
of 115 human atypical and plexiform neurofibromas (n = 24) and MPNSTs (primary, n = 38; 
recurrent, n = 32; MPNST, n = 21) was used for immunohistochemical staining. TMAs were 
constructed as previously described. (89)  
Cell lines  
MPNST cell lines used in this study include three NF1-associated MPNST cell lines 
(S462 [provided by Dr. Brian Rubin, The Cleveland Clinic and The Cleveland Clinic Lerner 
College of Medicine, Case Western Reserve University, Cleveland, OH] and ST88 and 
MPNST92-417/T265 [provided by Dr. Jonathan Fletcher, Brigham and Women’s Hospital, 
Boston, MA]), and two sporadic MPNST cell lines (STS26T [provided by Dr. Steven Porcelli, 
Albert Einstein College of Medicine, Bronx, NY] and MPNST724 [provided by Dr. Jonathan 
Fletcher]). Primary human adult normal Schwann cell (NSC) cultures were provided by Dr. 
Patrick Wood (University of Miami, Miami, FL) or purchased from ScienCell Research 
Laboratories. MDA-MB-231, MDA-MB-436, and T47D breast cancer cells were purchased 
from the MD Anderson Cancer Center characterized cell line core. MPNST cells were grown 
in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 100U/ml penicillin, and 100μg/ml streptomycin. MPNST cell lines with Cockayne 
syndrome B overexpression (CSBOE) or CSB shRNA were grown in DMEM with 10% FBS, 
100U/ml penicillin, and 100μg/ml streptomycin; positive transfectants were selected with 1 
μg/ml puromycin then grown under selective pressure. Schwann cells were grown in 
Schwann cell media (#1701, ScienCell Research Laboratories) supplemented with 5% FBS, 
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100U/ml penicillin, 100μg/ml streptomycin, and 1% Schwann cell growth supplement (#1752, 
ScienCell Research Laboratories). MDA-MB-231 and MDA-MB-436 were grown in 
Dulbecco’s modified Eagle medium:Nutrient mixture F-12 (DMEM F-12) supplemented with 
10% FBS, 100U/ml penicillin, and 100μg/ml streptomycin. T47D cells were grown in RPMI-
1640 media supplemented with 5% FBS, 100U/ml penicillin, and 100μg/ml streptomycin. DNA 
fingerprinting (short tandem repeat, STR) was conducted as previously described to verify 
the identity of all MPNST cell lines. (90)  
Antibodies and reagents 
The PARP inhibitors AZD2281 was purchased from ChemieTek (CT-A2281). For in vitro 
studies, the drugs were dissolved in dimethyl sulfoxide (DMSO) and stored at -80°C. For in 
vivo experiments, AZD2281 (50mg/kg/day) was dissolved in PBS, 10% DMSO, and 10% 2-
hydroxypropyl-β-cyclodextrin (HPCD). The DNA-PK inhibitor NU7026 was purchased from 
Selleck Chemicals (S2893). For in vitro studies the drug was dissolved in dimethyl sulfoxide 
(DMSO) and stored at -80°C. Commercially available antibodies were used for western blot 
or immunohistochemical (IHC) detection of PARP1 (9542, Cell Signaling Technology), 
PARP2 (PA1-4280, ThermoFisher Scientific Pierce) and (SAB2500751, Sigma-Aldrich), PAR 
(4335-AMC-050, Trevigen Inc) and (ALX-084-220-R100, Enzo Life Sciences, Inc.), gamma-
H2AX (2577, Cell Signaling Technology), CSB (10459, Santa Cruz Biotechnology), DNA-
PKcs (4602, cell signaling), DNA-PKcs Ser2056 (124918, Abcam), Ki67 (CRM325, Biocare 
Medical), cleaved caspase 3 (CC3; CP229, Biocare Medical), cyclin B1 (752, Santa Cruz 
Biotechnology), and β-actin-HRP (47778-HRP, Santa Cruz Biotechnology). Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed using the TdT-
FragEL™ DNA Fragmentation Detection Kit according to the manufacturer’s instructions 
(QIA33, EMD Millipore). The pEGFP-Pem1 system HR and NHEJ plasmids were provided by 
Dr. Vera Gobunova (University of Rochester, Rochester, NY). The CSB OE plasmid (pLenti-
GIII-CMV-hERCC6-HA; LV150273) and viral packaging vectors (LV053) were purchased 
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from Applied Biological Materials British Columbia, Canada. Viral packaging was performed 
by the MD Anderson Cancer Center shRNA and ORFeome Core. ERCC6 shRNA (Individual 
Human SMARTvector 2.0 Lentiviral shRNA particles) were purchased from ThermoFisher 
Scientific (VSH6063). Polybrene (sc-134220, Santa Cruz Biotechnology) and puromycin 
(400-128P, Gemini Bio-Products) were used for shRNA transductions. Restriction enzymes, 
ISCE1 and HindIII, were purchased from New England Biolabs and used according to New 
England Biolabs established conditions and protocols.  
ERCC6 shRNA transductions 
Approximately 5x105 MPNST cells were trypsinized, centrifuged, and resuspended in 1 
mL of DMEM supplemented with 5% FBS. Polybrene (1μg/ml) was added to each cell 
suspension, which were subsequently plated into six well tissue culture plates. Approximately 
5.0x106 viral particles were added to each well and incubated at 37°C for 8 hours. The media 
was then changed to DMEM supplemented with 10% FBS and incubated at 37°C for an 
additional 64 hours. Cells were grown under selective pressure (1.0µg/ml puromycin) for 
subsequent experiments. Knockdown of CSB was confirmed by western blot.    
MTS assays 
CellTiter96 AQueous One Solution Cell Proliferation Assays [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] (G3580, 
Promega) were used to evaluate cell proliferation per the manufacturer’s instructions. Briefly, 
cells were seeded in 96-well plates in 100µL of media. Attached cells were subsequently 
treated with AZD2281 and incubated with drug for 96 hours or 7 days (drug and media 
changed after 96 hours). MTS reagent was added to each well and incubated for 1-2 hours 
at 37°C. Absorbance was measured at a wavelength of 490nm. The absorbance values of 
treated cells were represented as a percentage of the absorbance of untreated cells. The 
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half-maximal effective concentration (EC50) of AZD2281 was determined using nonlinear 
regression log(inhibitor) vs. response (four parameters) curve fitting in GraphPad Prism 
version 6.05. 
Clonogenic assay  
Clonogenic assays were conducted by plating 100-500 MPNST cells in 6-well plates. 
Cells were then treated with DMSO or AZD2281 in DMEM for approximately 2 weeks. The 
media was removed, and the cells were washed twice with phosphate-buffered saline (PBS). 
The cells were fixed with 5% gluteraldehyde for 20 minutes and then washed and stained 
with 0.1% crystal violet in 20% methanol for at least 1 hour. The wells were washed with water 
and allowed to dry. Pictures were captured digitally and individual clones were counted 
manually. Clones of treated cells were represented relative to the untreated control.  
 Western blot analysis 
Western blot analyses were conducted according to previously published standard 
methods. (91) Densitometry was assessed using the ImageJ Gel Analysis tool version 1.49 
(NIH). 
Flow cytometry 
Cell cycle progression was measured by propidium iodide (PI) staining followed by 
fluorescence activated cell sorting (FACS) analysis. Cells were incubated with AZD2281 for 
24 hours and subsequently fixed in 70% ethanol. Fixed cells were resuspended in a PI 
staining solution (75μg/mL PI and 10μg/mL RNAse A). For evaluation of apoptosis, cells were 
treated with AZD2281 for 96 hours. Apoptosis was measured via Annexin V-Fluorescein 
isothiocyanate (Annexin V-FITC)/PI staining and FACS analysis with the FITC Annexin V 
Apoptosis Detection Kit I (556547, BD Biosciences) per the manufacturer’s 
recommendations. Cells reported as apoptotic include those in early and late phase 
apoptosis. Cell cycle and apoptosis samples were analyzed with the use of a Gallios flow 
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cytometer (Beckman Coulter Inc.) by the Flow Cytometry and Cellular Imaging Core at MD 
Anderson. Data from these experiments were analyzed with the use of the Multicycle program 
in FCS Express (De Novo Software).   
PARP activity assay 
PARP activity assays were performed by using the Trevigen Universal PARP 
Colormetric Assay Kit (4677-096-K, Trevigen Inc) according to the manufacturer’s instructions 
with the following modifications. Cells were seeded in six-well plates at approximately 50% 
confluency. The cells were then treated with AZD2281 and incubated for 24 hours at 37° C. 
Endogenous PARP activity was established without AZD2281 pretreatment. Cellular protein 
was extracted by scraping using the Cell Extraction Buffer (1x PARP Buffer [20X PARP buffer 
provided in kit diluted in water], 0.4M NaCl, 0.9% Triton X-100, 0.4nM PMSF, cOmplete 
Protease Inhibitor Cocktail Tablets [11697498001, Roche]). The suspension was centrifuged 
at 4°C for 10 minutes at >10,000g; the supernatant was extracted and the protein 
concentration was measured. 
Histone-coated strip wells were hydrated by using 1x PARP buffer for 30 minutes at 
room temperature; three wells per condition were used. The positive control wells contained 
diluted PARP-HSA enzyme (provided in kit), 1x PARP buffer, and 1x PARP cocktail (10x 
PARP cocktail provided in kit, 10x Activated DNA provided in kit, and 1x PARP buffer) at a 
final volume of 50µl. The negative control wells contained DMSO, 1x PARP buffer, and 1x 
PARP cocktail at a final volume of 50µl. The experimental wells included 10µg pretreated cell 
lysate in a total volume of 25μl, and 1x PARP cocktail at a final volume of 50µl. The wells 
were incubated for 1 hour at room temperature. The remainder of the experiment was 
performed according to the manufacturer’s instructions. The absorbance values of three wells 
from each experiment were averaged and the absorbance values of treated cells were 
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represented as a percentage of the absorbance of untreated cells. The data were represented 
as the average of two experiments with the standard error of the mean (SEM).  
RNA sequencing 
Total RNA was prepared using the RNeasy Mini Kit (74104, Qiagen) according to the 
manufacturer’s protocol. RNA sequencing was performed by the MD Anderson Cancer 
Center Sequencing and Microarray Facility with an Illumina HiSeq2000 sequencer. The raw 
reads were aligned to the human reference genome build hg19, using Tophat2 RNASeq 
alignment software. The mapping rate was 95.27% overall across all the samples in the 
dataset. HTseq-Count was used to quantify the gene expression counts from Tophat2 
alignment files. Differential expression analysis was performed on the count data using R 
package DESeq2. P-values obtained after multiple binomial tests were adjusted using FDR 
(BH). 
TaqMan PCR confirmation of RNAseq results 
Total RNA was extracted from cell lines using the RNeasy Mini Kit according to the 
manufacturer’s protocol. RNA was converted into cDNA using the iScript cDNA synthesis kit 
(1708890, Bio-Rad Laboratories) via the kit protocol. Excision repair cross-complementation 
group 6 (ERCC6) expression was confirmed using TaqMan PCR (Hs00972920_m1 primer: 
4331182, ThermoFisher Scientific) according to the manufacturer’s instructions. 
pEGFP-Pem1 system transfection  
The pEGFP-Pem1 plasmid system was a kind gift from the Vera Gorbunova laboratory 
(University of Rochester). (92,93) The HR plasmid of the pEGFP-Pem1 system was linearized 
by I-SceI digestion. 500ng of the linearized plasmid was transiently transfected into 
approximately 5x105 cells using the Neon transfection system according to the manufacturer’s 
instructions (ThermoFisher Scientific) along with the transfection control plasmid pDs-Red2 
(100ng). The electroporation parameters were 1350V (pulse voltage), 20ms (pulse width), 2 
pulses (pulse number) for cell lines. The cells were then plated in DMEM supplemented with 
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10% FBS. GFP was measured by flow cytometry 72 hours post transfection. The pEGFP-
Pem1 system also contains a plasmid to measure NHEJ efficiency. DSBs were induced by I-
SceI or Hind-III and the transfection proceeded similar to the HR plasmid. The data was 
reported as a ratio of green (indicating efficient HR in the cell) to red (indicating a transfected 
cell). Cells were analyzed with the use of a LSR Fortessa flow cytometer (BD Biosciences) 
located in the Flow Cytometry and Cellular Imaging Core at MD Anderson. Data from these 
experiments were analyzed with the use of the Multicycle program in FCS Express (De Novo 
Software).       
Metaphase spread 
Cell lines were treated with DMSO, 2.5µM AZD2281, 500nM NU7026, or combination 
treatment for 72 hours. Chromosome analysis was performed in duplicate at the UTMDACC 
Molecular Cytogenetics Facility (funded by the Center for Genetics and Genomics). 
Metaphase spreads from each sample were photographed using a Nikon 
80i microscope equipped with karyotyping software from Applied Spectral Imaging (ASI) Inc.  
The samples were scored for structural aberrations including chromosomal breaks, 
fusions, fragments, and radial structures. Thirty-five cells per plate and condition were 
evaluated. 
 CPD ELISA 
MPNST cells were plated in 6 well dishes to approximately 50% confluency. Prior to UV 
exposure, the wells were washed with PBS and the media was replaced with 500µl PBS. The 
dishes were then exposed to 256J/m2/min UVB using the FS40 lamp. (94) Immediately after 
exposure, the 0hr time point was harvested for cell lysates and pelleted for DNA extraction 
and use in the cyclobutane pyrimidine dimer (CPD) enzyme- linked immunosorbent assay 
(ELISA). The media in the remaining wells was replaced with DMEM supplemented with 10% 
fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin and harvested at the 
corresponding time points. DNA extraction was then performed using the QIAamp DNA Mini 
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Kit. The OxiSelect™ UV-Induced DNA Damage ELISA Kit (STA-322, Cell Biolabs) was then 
carried out according to the manufacturer’s instructions.  
In vivo animal models  
All animal procedures and care were approved by The University of Texas MD Anderson 
Cancer Center Institutional Animal Care and Usage Committee (IACUC). Animals received 
humane care as per the Animal Welfare Act and the NIH "Guide for the Care and Use of 
Laboratory Animals." Animal models were utilized as previously described. (95,96) Trypan 
blue confirmed viable MPNST724 cells (2x106 in 0.1mL of PBS/mouse) or STS26T cells 
(2x106 in 0.1mL of PBS/mouse) were injected into the flank of 6–week-old female hairless 
severe combined immunodeficient (SCID) outbred mice (Crl:SHO-PrkdcscidHrhr, Strain Code: 
474) (474-SCID Hairless, Charles River Laboratories) (MPNST724: vehicle group n=9 and 
AZD2281 group n=8; STS26T: n=8/for each treatment group), and growth was measured 
twice weekly. When average tumor volumes reached 50 mm3, the mice were assigned to two 
treatment groups: (a) control (vehicle only) and (b) AZD2281. AZD2281 (50mg/kg/daily, 
intraperitoneal injection [IP]) resuspended in PBS, 10% DMSO, and 10% 2-hydroxypropyl-β-
cyclodextrin (Sigma-Aldrich, St. Louis, MO) was used. Mice were monitored for tumor size, 
body weight, and well-being, and were euthanized when control group tumors reached an 
approximate volume of 1500 mm3. Tumors were resected, weighed, and fixed in formalin and 
paraffin-embedded for IHC studies.  
An experimental lung metastasis MPNST model was used to evaluate metastatic 
growth. This model has been described previously. (96)  Viable STS26T cells  were injected 
as cell suspensions (1x106 in 0.1mL of PBS/mouse) into the tail vein of 6–week-old female 
hairless severe combined immunodeficient (SCID) outbred mice (Crl:SHO-PrkdcscidHrhr, 
Strain Code: 474). Mice were monitored for 3 weeks (a time point by which 95%-100% of 
mice develop established lung metastases). (97) Mice were then assigned to the following 
treatment groups: (a) control (vehicle only) and (b) AZD2281 (50mg/kg/d, IP). AZD2281 
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resuspended in PBS, 10% DMSO, and 10% 2-hydroxypropyl-β-cyclodextrin was used. Mice 
were euthanized when physical signs of disease were present (weight loss >20% of baseline, 
difficulty of breathing, hunched posture, pallor, impaired ambulation, and lethargy). Lungs 
were resected, weighed, and examined for macroscopic lung metastases; these tissues were 
then fixed in formalin and paraffin-embedded for IHC studies. Survival studies proceeded as 
above; however, mice were sacrificed individually when euthanasia was required.  
IHC analysis 
PARP1 and PARP2 immunostaining was scored by two independent observers (AJL 
and GAA) for TMA analyses. Intensity scores were designated as negative (0), weak (1 and 
2), or strong (3). The percentage of cells staining positive was evaluated on a scale of 0-
100%. A combined score ranging from 0-300 was obtained from the product of the intensity 
and cells-positive scores. Xenograft-derived specimens were analyzed for markers of cell 
proliferation (Ki67), cell cycle arrest (cyclin B1), inhibitor specificity (PAR), and apoptosis 
(CC3 and TUNEL). Representative images of the TMA and xenograft- derived specimens 
were captured at 200x and 400x total magnification, respectively, using an Olympus 
microscope (BX41) and camera (DP72) with Olympus cellSens Standard v1.5 software.  
Statistical analyses 
Differences among expression of PARP1 and PARP2 between tumor types were 
evaluated using Mann-Whitney U tests. Univariate Cox proportional hazards models were 
used to assess the potential prognostic significance of PARP1 expression in primary and 
recurrent MPNST samples and further visualized utilizing univariate Kaplan-Meier curves. 
Two-sided p-values <0.05 were considered statistically significant. All analyses were 
performed using SPSS version 21. 
Cellular assays were repeated at least two times; the mean and SEM were calculated 
for each assay. The mean and standard deviation were calculated for xenograft experiments. 
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Correlation analysis between the fold change expression of CSB and the EC50 value of 
AZD2281 was established using Spearman’s correlation. Significance of findings was 
assessed using a two-tailed Student's t-test (p<0.05 = *; p<0.001 = ***). 
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Chapter 3 
PARP inhibition in vitro and in vivo 
This chapter is based upon the citation below and has been reprinted with permission from 
Taylor and Francis: [Cancer Biology and Therapy], copyright 2015.  
Kivlin, C. M. et al. Poly (ADP) Ribose Polymerase Inhibition: A Potential Treatment of 
Malignant Peripheral Nerve Sheath Tumor. Cancer biology & therapy, 0, 
doi:10.1080/15384047.2015.1108486 (2015). 
PARP1 and PARP2 are highly expressed in MPNST tissue samples. 
To determine the expression of PARP1 and PARP2 in human tumor samples, we 
performed IHC on a clinically annotated TMA containing patient samples of neurofibroma, 
primary MPNST, recurrent MPNST, and metastatic MPNST (Figure 11). The overwhelming 
majority of MPNST samples were positive for PARP staining. Overall, moderate to high 
expression of PARP1 and PARP2 was observed (Table 1).  
 
Figure 11. PARP1 and PARP2 are highly expressed in MPNST tissue compared to 
neurofibroma. MPNST TMA stained for PARP1 and PARP2. Images were captured at 200x 
magnification. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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Table 1. Mean expression of PARP1 and PARP2 combined score (0-300) and percentage of 
tumors with positive staining in neurofibroma and MPNST. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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While there was differential expression of PARP1 and PARP2 between primary, 
recurrent, and metastatic MPNST samples with regard to percent positive cells, nuclear 
intensity, and combined score, the clinical relevance of these minor variations is negligible as 
the overall expression levels remain high (Table 2 and Table 3). 
 
 
Table 2. Mean expression of PARP1 and PARP2 percentage of staining, nuclear intensity, 
and combined score in neurofibroma and MPNST disease states.  
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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Table 3. Summary of PARP1 and PARP2 distribution. PARP percentage of expression 
and nuclear intensity was scored from the MPNST TMA. The P value to determine the 
significance of distribution between disease states is shown. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
 
In addition, we evaluated whether PARP1 expression correlated with the survival 
outcomes of MPNST patients. Although not statistically significant, a trend towards better 
survival was observed in patients with tumors expressing low levels of PARP1 when 
compared to patients that had tumors with moderate to high expression (p = 0.165; HR 0.51, 
95% CI 0.19-1.32) (Figure 12; Table 4). PARP2 was not evaluated by log-rank comparison 
due to its homogenously uniform expression.    
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Figure 12.  PARP1 staining correlated to patient outcomes. Kaplan-Meier curve depicting 
a trend toward decreased survival in patients with moderate-high levels of PARP1 staining 
compared to low PARP1 staining, as determined by IHC. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
 
 
 
Table 4. Overall and disease- specific survival outcomes for MPNST patients determined by 
PARP1 percentage of staining, nuclear intensity, or combined score. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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PARP1 is highly expressed in MPNST cell lines. 
Based on the enhanced expression of PARP1 and PARP2 seen in our MPNST tissue 
samples, we assessed their expression in a panel of MPNST cell lines. An immunoblot of 
PARP1 and PARP2 suggested increased expression in MPNST cell lines versus the normal 
Schwann cell control (Figure 13).  
 
Figure 13. PARP1 and PARP2 are highly expressed in MPNST cell lines compared to 
normal Schwann cells. Immunoblot of PARP1 and PARP2 in a MPNST cell panel and 
normal Schwann cell control.  
 
 
PARP activity is enhanced in MPNST cell lines. 
PARP1 and PARP2 modify acceptor proteins through PARylation and thus influence 
their cellular function. Therefore, PAR expression can be used as a marker of PARP catalytic 
activity. We performed western blot analysis to interrogate a panel of MPNST cell lines 
(sporadic: MPNST724 and STS26T; NF1-associated: S462 and ST88) for endogenous PAR 
expression. MPNST cell lines have enhanced PAR expression, suggestive of increased 
PARP activity compared with normal Schwann cells (NSCs), with MPNST724 cells showing 
the lowest expression of the MPNST cell lines (Figure 14). Because PARP activity is 
stimulated by DNA damage, increased endogenous PAR expression could indicate the 
relatively high levels of endogenous DNA damage in MPNST cell lines.  
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Figure 14. MPNST cell lines have enhanced PAR expression. PAR immunoblot of MPNST 
cell panel and normal Schwann cells. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
 
To validate that enhanced PARP expression is representative of endogenous PARP 
activity in MPNST cell lines, untreated MPNST cell lines and NSCs were used in a modified 
Universal PARP Colorimetric Assay. PARP activity was found to be more than three-fold 
higher in MPNST cell lines compared to NSCs in this cell-free system (Figure 15). 
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Figure 15. MPNST cell lines have increased PARP activity compared to NSCs. 
Endogenous PARP activity in untreated MPNST cells and normal Schwann cells (n=4). Error 
bars represent standard error of the mean; (*= p<0.05). 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
 
 
 
AZD2281 is a highly effective single-agent inhibitor of MPNST in vitro. 
Before assessing the effect of AZD2281 on MPNST tumorigenicity, we evaluated  
the efficacy of this inhibitor to block PARP activity. A panel of MPNST cell lines was treated 
with increasing doses of AZD2281 for 24 hours and evaluated by the modified Universal 
PARP Colorimetric Assay. AZD2281 treatment resulted in a dose-dependent decrease in 
PARP activity in all MPNST cell lines (Figure 16).  
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Figure 16. PARP inhibition decreases PARP activity in MPNST cell lines. A panel of 
MPNST cell lines were pretreated for 24 hours with AZD2281 and subjected to a modified 
PARP activity assay (26T, ST88, and 462 n=3; 724 n=2). Error bars represent standard error 
of the mean; * = p<0.05; *** = p<0.001. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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Treatment of MPNST cell lines with elevated concentrations of AZD2281 for 96 hours resulted 
in a proportional decrease in cell proliferation. All EC50 values for the MPNST cell panel were 
in the micromolar range (2.92 – 12 μM) with no variation in sensitivity between the sporadic 
and NF1-associated cell lines. In comparison, normal Schwann cell lines treated with the 
same dose of AZD2281 showed only a slight decrease in cell proliferation. EC50s ranged 
from 18μM to greater than 20μM, which was the highest treatment dose used (Figure 17). 
Compared to cell lines known to be sensitive or resistant to AZD2281 as determined by their 
AZD2281 EC50 values, the EC50s of MPNST cell lines more closely resemble those of the 
the known sensitive cell lines (Table 5). Additionally, AZD2281 decreased the clonogenic 
potential of MPNST cell lines in a dose-dependent manner (Figure 18).  
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Figure 17. PARP inhibition significantly inhibits MPNST cell proliferation in vitro 
compared to normal Schwann cells. MPNST and NSC cell lines were treated for 96 hours 
with AZD2281 and cell proliferation was assessed by MTS assay (n=3; ST88 n=4). Error bars 
represent standard error of the mean; * = p<0.05; *** = p<0.001. 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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Table 5. Cell line sensitivity to AZD2281. MPNST cell lines have AZD2281 EC50s more 
similar to known sensitive cell lines. Cells treated with AZD2281 for 96 hours and assessed 
by MTS assays to acquire EC50 values. 
 
Figure 18. AZD2281 treatment decreases the clonogenic potential of MPNST cells. 
Representative images of clonogenic assays wells. Graph of replicate experiments with 
clones of treated cells represented relative to the untreated control (724 n=2; 462 and ST88 
n=4; 26T n=5). Error bars represent standard error of the mean; (*=p<0.05; ***=p<0.001). 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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Based on the reduced cell proliferation and clone-forming ability observed, we wanted 
to evaluate cell cycle distribution and apoptosis after AZD2281 treatment. A significant 
increase in the G2/M phase of the cell cycle was observed following a 24-hour treatment with 
AZD2281 (Figure 19).  
 
 
Figure 19. AZD2281 induces a dose-dependent cell cycle arrest. PI FACS analysis after 
24 hour treatment with AZD2281 in MPNST cell lines (26T and ST88 n=3; 724 and 462 n=4). 
Error bars represent standard error of the mean; (*=p<0.05).  
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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This analysis also revealed that AZD2281 induced apoptosis in MPNST cells after 96 hours 
of treatment (Figure 20). These in vitro responses prompted us to evaluate the functional 
effects of PARP inhibition on MPNST tumor growth.  
 
 
 
Figure 20. AZD2281 induces apoptosis in a dose-dependent manner. Annexin V-FITC/PI 
FACS analysis after 96 hour AZD2281 treatment in MPNST cell lines (n=3). Error bars 
represent standard error of the mean; (*=p<0.05).  
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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AZD2281 decreases MPNST local tumor growth 
To evaluate the effect of AZD2281 on MPNST local tumor growth, we utilized two 
subcutaneous xenograft mouse models using the MPNST724 and STS26T cell lines. Mice 
were treated with daily 50mg/kg AZD2281 (n=8) or vehicle (n=9) (IP). AZD2281 treatment 
significantly reduced tumor volume and weight compared to the vehicle group (Figure 21 and 
Figure 22). The effects of AZD2281 treatment were validated by IHC analyses. AZD2281 
resulted in a decrease in cell proliferation as measured by Ki67 staining. Furthermore, a 
decrease in the intensity of PAR staining was observed after AZD2281 treatment, supporting 
the specificity of the inhibitor for PARP enzymatic activity. Increased cyclin B1 staining 
suggested an accumulation of cells in the G2/M phase. Furthermore, an increase in tumor 
cell apoptosis (indicated by TUNEL and CC3 positivity) was found after PARP inhibition. 
These results support our observations in vitro: that MPNST724 cells were slightly more 
sensitive to PARP inhibition than STS26T cells.  
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Figure 21. AZD2281 abrogates local tumor growth in a MPNST724 model. Seventeen 
female hairless SCID mice were injected with 2x106 MPNST724 cells and treated with 
AZD2281 for 23 days. Treatment groups included vehicle (10% HPCD, 10% DMSO, and 
PBS) (n=9) and 50mg/kg/day AZD2281 (n=8). Tumor volume and weight were assessed. 
Tumor samples were stained for Ki67, PAR, cyclin B1, CC3, and TUNEL. Original photos 
were captured at 400X magnification. Error bars represent standard deviation; *** = p<0.001.  
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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Figure 22. AZD2281 abrogates local tumor growth in a STS26T model. Sixteen female 
hairless SCID mice were injected with 2x106 STS26T cells and treated with AZD2281 for 19 
days. Treatment groups included vehicle (10% HPCD, 10% DMSO, and PBS) (n=9) and 
50mg/kg/day AZD2281 (n=8). Tumor volume and weight were assessed. Tumor samples 
were stained for Ki67, PAR, cyclin B1, CC3, and TUNEL. Original photos were captured at 
400X magnification. Error bars represent standard deviation; *** = p<0.001.  
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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PARP inhibition reduces experimental MPNST lung metastases 
MPNSTs have a strong propensity to metastasize, primarily to the lung, within two years 
of initial disease presentation; therefore, we evaluated whether PARP inhibition would affect 
metastatic growth. (99,100) Because our established mouse models do not spontaneously 
metastasize, we utilized an experimental lung metastasis model as previously described. (96) 
After 21 days of treatment the experiment was concluded; at this time all mice in the vehicle 
group had macroscopic MPNST lung metastases, whereas 3 out of 7 (43%) had macroscopic 
metastases in the treatment group. However, microscopic lung metastases were detected in 
all samples, regardless of treatment. No significant difference in lung weight between 
treatment groups was observed (Figure 23).  
Figure 23. AZD2281 decreases macroscopic metastasis growth but does not affect 
lung weight. Mice were injected via tail vein with STS26T cells and subsequently treated with 
vehicle (n=7) or AZD2281 (n=7) for 21 days. Percentage of macroscopic and microscopic 
lung metastases in vehicle and AZD2281-treated mice. Representative images of gross lung 
and H&E staining. Graph of lung weights in the vehicle and treatment groups, mean and SEM 
depicted in the scatter plot (p=0.47). 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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AZD2281 long-term treatment increases survival 
We then evaluated whether AZD2281 treatment affected survival in a metastatic setting. 
To answer this question, we utilized the experimental lung metastasis model used in the prior 
section, but sacrificed the animals individually when euthanasia was mandated due to weight 
loss >20% of baseline, difficulty of breathing, hunched posture, pallor, impaired ambulation, 
or lethargy. Overall, treatment continued for 60 days at which point 5 out of 7 (71%) mice in 
the AZD2281 treatment group were alive versus 0 out of 7 (0%) mice in the control group 
(Figure 4). These results indicated that treatment with AZD2281 significantly increased the 
survival of mice with metastatic disease.  
 
Figure 24. AZD2281 significantly improves survival in an in vivo model of metastatic 
MPNST. Female hairless SCID mice were injected with STS26T cells in the tail vein and 
treated with AZD2281 for 60 days. Treatment groups included vehicle (10% HPCD, 10% 
DMSO, and PBS) and 50mg/kg/day AZD2281. (*=p<0.05). 
Reprinted with permission from Taylor and Francis: [Cancer Biology and Therapy] (98), 
copyright 2015.  
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Chapter 4 
Mechanisms of PARP inhibition sensitivity 
This chapter is based upon the citation below. 
Kivlin, C. M. et al. A Potential Mechanism of Malignant Peripheral Nerve Sheath Tumor 
Sensitivity to Poly (ADP) Ribose Polymerase Inhibition. In preparation. 
Multiple possible mechanisms of cancer cell line sensitivity to AZD2281  
A review of the literature from 2005 to 2015 revealed several dysregulated or mutated 
DNA damage signaling and repair genes that are associated with AZD2281 sensitivity in their 
respective models (Table 6). This prompted us to evaluate not only the specific DNA repair-
related genes dysregulated in MPNST, but also the efficiency of DNA double strand break 
repair pathways, specifically HR and NHEJ.  
 
Table 6. Mechanisms of sensitivity for AZD2281. Published mechanisms of sensitivity for 
AZD2281 from 2005-2015. 
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MPNST cell lines have DNA repair pathway deficiencies 
To interrogate the efficiency of NHEJ and HR in MPNST cell lines, we used the pEGFP-
Pem1 plasmid system established by V. Gorbunova. (92,93) The HR plasmid of the pEGFP-
Pem1 system is a reporter cassette that consists of two mutated copies of GFP-Pem1. In the 
first copy the green fluorescent protein (GFP) exon contains a 22 nucleotide deletion, 
therefore GFP cannot be reconstituted by a NHEJ event, and an insertion of two I-SceI 
recognition sites in inverted orientation. The second copy of GFP-Pem1 lacks the ATG start 
codon and the second exon of GFP (Figure 25). Upon induction of DSBs by I-SceI, a 
restriction enzyme (RE), the linearized plasmid is transiently transfected into the cells along 
with the transfection control plasmid pDs-Red2. Intact homologous recombination can then 
reconstitute an active GFP gene. GFP and RFP expression are reported as a ratio of green 
(indicating effective HR in the cell) to red (indicating a transfected cell). 
 
 
Figure 25. Reporter construct of the HR plasmid of the eGFP-Pem1 system. Reporter 
plasmid for analysis of HR. The reporter cassette consists of two mutated copies of GFP-
Pem1. In the first copy of GFP-Pem1, the first GFP exon contains a deletion of 22 nt and an 
insertion of two I-SceI recognition sites in inverted orientation. The 22 nt deletion ensures that 
GFP cannot be reconstituted by a NHEJ event. The second copy of GFP-Pem1 lacks the 
ATG and the second exon of GFP. Upon induction of DSBs by I-SceI, gene conversion events 
reconstitute an active GFP gene.  
Reprinted with permission from Elsevier: [Neoplasia] (93), Copyright 2009.  
59 
 
The eGFP-Pem1 system also contains a plasmid to measure NHEJ efficiency. GFP is 
separated by a 2.4 kb Pem1 intron containing an adenoviral exon that is flanked by HindIII 
and I-SceI restriction sites. The adenoviral exon inactivates the GFP activity, making the 
starting substrate GFP negative. Both sides of the adenoviral exon have HindIII/I-SceI 
restriction sites. Cleavage with either RE removes the Ad exon and if the cells have intact 
NHEJ, full length GFP will be expressed. Digestion with HindIII generates compatible ends 
which NHEJ can simply re-ligate; cleavage with I-SceI generates incompatible ends which 
need to be processed by NHEJ nucleases and polymerases before ligation (Figure 26). 
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Figure 26. Reporter construct of the NHEJ plasmid of the eGFP-Pem1 system. Reporter 
plasmid for analysis of NHEJ. The reporter cassette consists of a GFP gene under a 
Human cytomegalovirus (CMV) promoter with an engineered intron from the rat Pem1 gene, 
interrupted by an adenoviral exon (Ad). The adenoviral exon is flanked by I-SceI recognition 
sites in inverted orientation for induction of DSBs. In this construct, the GFP gene is inactive; 
however, upon induction of a DSB and successful NHEJ, the construct becomes 
GFP+. SA indicates splice acceptor; SA, splice donor; shaded squares, polyadenylation 
sites. HindIII generates compatible ends. I-SceI generates incompatible ends.  
Reprinted with permission from Elsevier: [Neoplasia] (93), Copyright 2009 and reprinted from 
Fattah, F. et al. Ku regulates the non-homologous end joining pathway choice of DNA double-
strand break repair in human somatic cells. PLoS genetics 6, e1000855, 
doi:10.1371/journal.pgen.1000855 (2010). 
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We used T47D breast adenocarcinoma cells as a positive control for the NHEJ and HR 
plasmids. MDA-MB-231 and MDA-MB-436 breast adenocarcinoma cell lines were used as a 
positive and negative control for the HR plasmid, respectively. There was no striking 
difference in the NHEJ efficiency of all MPNST cell lines compared to the T47D control; with 
S462 having the greatest NHEJ efficiency. However, MPNST cell lines had HR levels similar 
to the MDA-MB-436 cell line, known to be HR deficient due to a BRCA1 mutation (101), and 
substantially lower levels than the HR-intact MDA-MB-231 and T47D cell lines (Figure 27). 
This indicates that MPNST cells lines have deficient HR which could contribute to their PARP 
inhibitor sensitivity. Furthermore, the activity of NHEJ in MPNST could also contribute to 
PARP inhibitor sensitivity by increasing the amount of inherent chromosomal instability in 
these cells. 
Figure 27. MPNST cell lines have deficient HR repair. Cells were transfected with the 
NHEJ or HR eGFP-Pem1 plasmid and incubated for 72 hours. Green fluorescence indicates 
intact NHEJ or HR, and red fluorescence represents transfection efficiency. Fluorescence 
was assessed by flow cytometry. Error bars represent SEM (n=2). (*=p<0.05).  
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PARP inhibition enhances NHEJ activity which results in increased chromosomal 
instability.  
Patel et al. showed that in homologous recombination deficient ovarian cancer cell lines, 
PARP1 acted as a negative regulator of NHEJ activity. (86) Although NHEJ is an efficient 
method of double strand DNA repair, because it does not utilize a template strand for repair, 
it is an inherently error- prone mechanism. They suggest that in HR deficient cell lines that 
have been treated with a PARP inhibitor, despite the accumulation of unresolved DNA DSBs 
that develop, which are highly toxic to the cell, the main cause of cell death is the enhanced 
genomic instability due to increased activity of NHEJ. They further show this by blocking 
NHEJ with a DNA-PKcs inhibitor, which reversed the NHEJ activity and genomic instability 
and lethality of PARPi even in HR deficient cells. Therefore, treatment with a PARP inhibitor 
causes increased activity of NHEJ and consequently increased chromosomal instability due 
to the errors induced by NHEJ. This instability can stall the replication fork and eventually 
lead to collapse of the replication fork and cell death. To determine if PARP inhibition 
increases NHEJ activity in MPNST, we treated cells with AZD2281 for 72 hours and 
performed an immunoblot for DNA-PKcs Ser2056. In contrast to Patel et al. which showed 
no endogenous activation of DNA-PKcs, MPNST cell lines had a strong baseline expression 
of DNA-PKcs Ser2056. We observed stable expression of phosphorylated DNA-PKcs with 
increasing doses of AZD2281 treatment, indicating no change in DNA-PKcs activity (Figure 
28). Furthermore, 72 hour treatment with increasing doses of the DNA-PKcs inhibitor, 
NU7026, decreased phosphorylated DNA-PKcs (Ser2056) in a dose dependent manner, 
showing the efficacy of this inhibitor.  
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Figure 28. NU7026 decreases DNA-PKcs activity. Cells were treated with DMSO, 1.25-
5µM AZD2281 and 250-4000nM NU7026 for 72 hours then immunoblotted for DNA-PKcs 
(Ser2056) and total DNA-PKcs. 
 
We then wanted to determine if treatment with a NU7026 could decrease the NHEJ 
activity enhanced by PARP inhibition. Therefore, we treated MPNST cell lines with 2.5 µM 
AZD2281, 500 or 1000nM NU7026, or a combination with two different doses of NU7026 
(500- low combination or 1000nM- high combination) for 72 hours and performed an 
immunoblot for DNA-PKcs Ser2056. We observed stable phosphorylated DNK-PKcs 
expression with AZD2281 treatment alone, with a slight decrease in expression when the two 
inhibitors were combined, especially at the higher combined dose. (Figure 29). This 
substantiates a slight role for AZD2281 in the increase of NHEJ activity.   
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Figure 29. Combination treatment decreases DNA-PKcs activity. Cells were treated with 
DMSO, 2.5µM AZD2281, 500nM NU7026, or combination for 72 hours then immunoblotted 
for DNA-PKcs (Ser2056) and total DNA-PKcs. 
To further determine the effect of PARP inhibition on MPNST chromosomal instability, 
we treated MPNST cell lines with AZD2281 and NU7026, alone and in combination, and 
performed a chromosomal analysis via metaphase spread. These cells were scored for 
chromosomal breaks, fragments, fusions, and radial structures, all markers of genomic 
instability. In the untreated control we determined the base line level of genomic instability in 
each MPNST cell lines. Treatment with AZD2281 alone caused a substantial increase the 
observed chromosomal breaks, indicating increased genomic instability. Treatment with 
NU7026 only marginally increased the level of genomic instability from base line. However, 
dual treatment showed a varied cell line-specific effect in the number of chromosomal breaks 
compared to the AZD2281 treatment group, with S462 showing the greatest decrease in 
NHEJ after combination treatment (Figure 30). This could indicate that the damage induced 
by PARP inhibition in MPNST cell lines that leads to cell death is partly due to NHEJ activity 
which causes chromosomal instability and that altered dosing could further enhance the effect 
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of combination treatment.  
 
Figure 30. PARP inhibition increases chromosome breaks which is mitigated by 
combination treatment. Cells were treated with DMSO, 2.5µM AZD2281, 500nM NU7026, 
or combination for 72 hours then analyzed for chromosomal aberrations, including 
chromosomal breaks (red arrow), fusions (green x), fragments (blue asterisk), and radial 
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structures, via metaphase spread. Representative images and graphs of total chromosomal 
breaks are shown.  
Several DNA repair-related genes are dysregulated in MPNST cell lines relative to NSCs  
Due to the overwhelming evidence in the literature that cells are sensitive to PARP 
inhibition when there is a deficiency in a DNA repair gene, we assessed the expression level 
of DNA repair-related genes in MPNST cell lines compared to NSCs using RNA sequencing 
(RNAseq). (102) As a deficiency in HR or other DNA repair gene defects combined with a 
PARP inhibitor is strongly associated with synthetic lethality, we chose to focus on 
downregulated DNA repair-related genes. The top five downregulated genes, based on log2 
fold change in at least two out of the four MPNST cell lines assessed, are shown in Table 7. 
Relative to NSCs, ERCC6, essential for the transcription coupled repair sub-pathway of NER, 
is the most downregulated DNA repair-related gene. Likewise, the fifth most downregulated 
gene, ERCC5, is an endonuclease essential for the common pathway of NER. The other top 
downregulated genes are involved in HR during meiosis (MutS Homolog 4 (MSH4) and DNA 
Meiotic Recombinase 1 (DMC1)), as well as regulation of the circadian clock (Period 
Circadian Clock 1 (PER1)). These results indicate multiple dysregulated DNA repair pathways 
in MPNST cell lines that could contribute to the observed PARP inhibitor sensitivity.  
Table 7. Downregulated DNA repair-related genes in MPNST cell lines. RNA sequencing 
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results for DNA repair-related genes in MPNST cell lines versus an NSC control. No change 
(NC) indicates no significant differential expression.  
 
 
 
 
ERCC6 has decreased transcript and protein expression in MPNST cell lines 
To validate the RNAseq results that indicate a substantial decrease in ERCC6 
expression, we performed qRT-PCR for our MPNST cell panel. There is decreased transcript 
expression of ERCC6 detected in MPNST cell lines versus a NSC control (Figure 31).  
 
Figure 31. ERCC6 transcript levels are lower in MPNST cell lines. A panel of MPNST cell 
lines were assessed by qRT-PCR for ERCC6 expression versus a NSC control. Error bars 
represent SEM (n=3). (*=p<0.05).  
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To further confirm our results, we performed immunoblot analysis for CSB, the protein 
encoded by ERCC6, using an NSC and MPNST cell panel. Full-length CSB is approximately 
168 kDa, while the CSB-PGBD3 fusion protein (first five exons of CSB and the piggyBac 
transposable element derived 3) is 140kDa. This fusion protein has not been shown to have 
a direct role in DNA repair; however, there could be an indirect effect through incorporation 
of the fusion protein instead of the full-length CSB which could limit effective repair of the 
DNA. (103) Fold change (FC) is determine by densitometry and is relative to each sample’s 
β-actin and adjusted to the NSC9674 sample present on both immunoblots. This revealed an 
average relative CSB expression of 2.5 in the NSC group versus 0.4 in the MPNST group, 
showing that NSCs have an overall greater expression of CSB as well as overall higher 
AZD2281 EC50 values (Figure 32). Interrogation by Spearman’s rank correlation revealed a 
positive correlation between FC and AZD2281 EC50 (r = 0.645; p = 0.0368), indicating a 
potential link between CSB expression and sensitivity of MPNST cell lines to AZD2281.  
Figure 32. ERCC6 has decreased protein expression in MPNST cell lines. Immunoblot 
of CSB in a panel of NSC and MPNST cell lines. Fold change (FC) was determine by 
densitometry and is relative to each sample’s actin and adjusted to the NSC9674 sample; 
(*=p<0.05). Spearman’s correlation was used to determine if CSB fold change correlated to 
AZD2281 EC50; (r = 0.645; *=p<0.05).  
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Alteration of CSB expression influences cancer cell line sensitivity to AZD2281  
Based on the correlation of CSB expression to AZD2281 EC50, we stably 
overexpressed CSB in MPNST cell lines in order to determine if there is an effect on sensitivity 
to PARP inhibition. MPNST cell lines were transduced with a CSB lentiviral vector in two 
separate transduction pools. Immunoblot confirmation of full length CSB overexpression was 
performed in each cell line. After a 7 day treatment with AZD2281, cell proliferation was 
measured by MTS assay (Figure 33).  In S462 and ST88 cells, overexpression of CSB caused 
an increase in the AZD2281 EC50 values Overall this shows a more prominent role for CSB 
in the sensitivity of these MPNST cells to PARP inhibition. However, in STS26T and 
MPNST724 cells, the overexpression of CSB has a minimal effect on the cell sensitivity to 
PARP inhibition. This suggests that although CSB expression affects MPNST sensitivity to 
AZD2281, there may be other players involved in the tumor cell response to treatment.  
  
Figure 33. CSB overexpression causes a subset of MPNST cell lines to be less 
sensitive to PARP inhibition. Immunoblots of CSB show increased expression of CSB after 
transduction of the lentiviral vector; n=3.  
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As a proof of principle that CSB expression affects PARP inhibitor (PARPi) sensitivity, 
we stably knocked down CSB via shRNA in the MDA-MB-231 cell line, known to be relatively 
resistant to PARP inhibition (Figure 34). (104) Knockdown of CSB caused a 3-6 fold decrease 
in the EC50 of AZD2281, further substantiating a role for CSB in PARPi sensitivity.  
 
Figure 34. CSB knockdown causes MDA-MB-231 cells to be more sensitive to AZD2281. 
Immunoblots of CSB show decreased expression of CSB after transduction of the CSB 
shRNA; n=3.  
CSB does not affect the efficiency of CPD repair 
To examine the functional effect of CSB expression, we used an ELISA (Cell Biolabs) 
recognizing cyclobutane pyrimidine dimers (CPDs), one of the main types of DNA damage 
induced by UV and repaired by the NER pathway. After treatment with 256J/m2/min of 
ultraviolet B (UVB), we harvested the cells from 0-24 hours, a time frame in which the majority 
of CPDs should be repaired, and assessed the level of CPDs (Figure 35). (105) While we 
expected overexpression of CSB to increase the efficiency of CPD repair compared to the 
non-targeting cells, we did not see a significant difference in the level of CPDs in the S462 or 
MPNST724 cell lines. Along the same lines, we also anticipated that the knockdown of CSB 
in the MDA-MB-231 cell line would decrease CPD repair efficiency compared to the non-
targeting cells, but in general, observed no drastic change. 
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To ensure that any decreased CPD levels seen in our ELISA was due to repair of the 
damage and not conversion to a double strand DNA break, we also evaluated the expression 
of gamma-H2AX in the UV treated cells from 0-24 hours. However, the expression pattern of 
gamma-H2AX was similar in each cell line regardless of CSB expression.  
Figure 35. Alteration of CSB expression does not affect the efficiency of CPD repair. 
Cells were treated with 256J/m2/min UVB then harvested from 0-24 hours and used for CPD 
ELISA and gamma-H2AX immunoblot. Error bars represent standard error of the mean (n=2); 
(*=p<0.05). 
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Chapter 5 
Discussion, Conclusions, and Future Directions 
MPNST is an aggressive subtype of STS for which surgical resection has been the 
standard of care for decades and continues to be the most effective treatment. Standard 
chemotherapy and radiotherapy have shown modest therapeutic benefit, restricted mostly to 
local control and disease stabilization. MPNSTs have a complex karyotype indicating a high 
baseline level of genomic instability and a potential DNA repair defect. Despite identification 
of chromosomal aberrations and specific recurring genetic alterations which could be targeted 
for therapeutic gain, several clinical trials have been conducted in MPNST and other sarcoma 
subtype patients with minimal observed responses.  (7,19-22,106-108) The aggressive nature 
of the disease is depicted in the dismal five-year survival rate of only 35-60%. Therefore, a 
novel targeted therapy is necessary to improve MPNST patient outcome.   
PARP inhibitors have been shown to be efficacious in two settings: by exploiting a 
genetic defect in the cells through synthetic lethality, especially a BRCA1/2 mutation or 
‘BRCAness’, and as a chemosensitizer to a conventional chemotherapy or radiotherapy. (46) 
AZD2281, a well-established PARP inhibitor, has been used in multiple preclinical studies 
including those in breast and lung cancer, and glioma models. (49,109,110) Furthermore, this 
inhibitor is now in Phase III clinical trials.  
To determine the utility of PARP inhibition in MPNST, we first evaluated the expression 
of PARP1 and PARP2 in neurofibroma and MPNST human tumor samples using a clinically 
annotated TMA. Overall, we found that all MPNST samples had a high level of PARP1 and 
PARP2 expression. PARP1 expression has been shown to be elevated in multiple 
malignancies including breast, ovarian, uterine, and lung; however, PARP2 has less variable 
expression patterns between normal and tumor tissue. (111,112) The increased level of 
PARP expression, as well as its ubiquitous expression pattern, supports the potential use of 
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PARPis in MPNST; however, the applicability of PARP staining to determine MPNST 
progression is limited. PARP2 was homogenously expressed in our MPNST TMA and 
therefore was not further evaluated. However, moderate to high PARP1 expression was 
shown to correlate with a worse patient prognosis, although no statistical significance was 
reached. This is similar to reports concerning breast cancer patients in which PARP1 
overexpression correlated with reduced disease-specific survival. (113,114) This suggests 
that MPNST patients with a high level of PARP1 expression would not only be a candidate 
for PARP inhibition treatment, but also warrant a more aggressive treatment plan or closer 
monitoring due to the more aggressive disease phenotype observed with increased PARP1 
staining. While these findings are intriguing, further evaluation is necessary to determine any 
clinical use of PARP staining in MPNST. Future studies should also consider larger MPNST 
populations to provide more statistical power, and include clinicopathologic factors (such as 
age, tumor location, tumor size, etc.) to correlate to PARP expression to find more/any 
associations. 
In this study, we evaluated the efficacy of the PARP inhibitor, AZD2281, in MPNST. We 
show that AZD2281 has a strong anti-MPNST effect as a single agent in vitro. Specifically, 
AZD2281 treatment decreased cell proliferation, at similar or lower concentrations than those 
used in models with established sensitizing genetic aberrations, and at comparable or shorter 
time points. (53,115,116) Furthermore, we observed that AZD2281 caused a substantial 
dose-dependent cell cycle arrest at 24 hours and significantly enhanced apoptosis at 96 
hours. This effect on the cell cycle and viability has been similarly observed after PARP 
inhibitor treatment in BRCA2 deficient esophageal squamous carcinoma cells and BRCA1/2 
deficient breast cancer cell lines, among others. (41,117) All MPNST cell lines tested have 
EC50 values in the micromolar range, and no sensitivity predilection between sporadic and 
NF1-associated cell lines was observed.  
To further determine whether PARP inhibition would be a useful therapeutic option, we 
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established the level of PARP1, PARP2, and PAR expression in a panel of MPNST cell lines 
using Western blotting. Increased PARP1, PARP2, and PAR expression was observed in 
MPNST cell lines compared to NSCs indicating PARP is a viable therapeutic target in 
MPNST. Of the MPNST cell line panel, MPNST724 cells had the lowest PAR expression. We 
further determined PARP activity using the modified PARP activity assay and observed 
uniform increased endogenous PARP activity in our MPNST cell lines compared to NSCs. 
Perhaps the discrepancy in the level of MPNST724 PARP activity between the immunoblot 
and the PARP activity assay is due to the cell-free nature of the PARP activity assay indicating 
true endogenous activation of PARP in MPNST724 cells is not as substantial. Furthermore, 
inhibition of PARP via AZD2281 pretreatment, decreased PARP activity in a dose-dependent 
manner in all MPNST cell lines, with MPNST724 cells showing the lowest response, further 
indicating its lower overall PARP activity level compared to the other MPNST cell lines. 
Interestingly, it has been suggested that increased PARP expression correlates with 
increased sensitivity to PARP inhibition. (118) In the setting of MPNST, MPNST724 cells 
displayed the greatest sensitivity to AZD2281 with an EC50 of 2.76µM. However, these cells 
also have the lowest level of PAR expression and response of PARP activity to AZD2281 
treatment. This indicates that while increased PARP activity may not always correlate with 
increased sensitivity to PARP inhibition.  
Based on these promising in vitro results, we evaluated AZD2281 in several in vivo 
models of MPNST.  To assess the effect of PARP inhibition on local tumor growth, we treated 
MPNST724 and STS26T subcutaneous xenograft mouse models starting at an average 
volume of 50mm3. While other studies with xenograft mouse models begin treatment when 
tumors reach approximately 200mm3, due to the rapid growth rate of untreated MPNST 
xenografts, we began treatment at a smaller volume in order to treat the mice for a meaningful 
amount of time before a tumor volume mandating euthanasia was reached. (49,96) 
Furthermore, MPNST patients, particularly those with NF1, can present with tumors greater 
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than 5cm at the time of diagnosis, therefore experimental treatment of a more established 
mass can better recapitulate this clinical presentation. (7) Three-week treatment of mice with 
AZD2281 resulted in a significant decrease in tumor growth compared to the untreated group 
and, interestingly, MPNST724 cells were more responsive to treatment than the STS26T. 
Although no disease regression was observed, PARP inhibition seemed to slow the 
progression of tumor growth. A previous report in a BRCA wild-type ovarian cancer xenograft 
also showed decreased progression of disease with AZD2281 treatment rather than disease 
regression. (119) The IHC analysis of subcutaneous tumors from both cell lines revealed a 
decrease in cell proliferation, as determined by lower Ki67 expression; specific targeting of 
PARP enzymatic activity as evidenced by decreased PAR staining; a possible G2/M phase 
cell cycle arrest indicated by increased cyclin B1 staining; and increased CC3 and TUNEL 
indicating induced apoptosis with AZD2281 treatment. These results show the potential 
benefits of PARP inhibition treatment for local MPNST disease. An orthotopic model of 
MPNST has been described in which tumor cells are injected into the sciatic nerve that more 
faithfully recapitulates the human disease and local tumor growth; however, this model has 
not been reproducibly established at our institution. (120) Future endeavors should explore 
this and other orthotopic models available to expand the potential utility of AZD2281 in vivo. 
Despite the high metastatic potential of MPNST which contributes to the aggressive 
nature of the disease, mouse models of MPNST do not incur spontaneous metastases. 
Therefore, to pursue the effect of PARP inhibition on metastasis in vivo, we used an 
experimental metastasis tail vein injection model using STS26T cells. We observed a 
decrease in the development of macroscopic lung metastases after PARP inhibition. All mice, 
regardless of treatment, had microscopic lung metastases suggesting that AZD2281 
treatment slowed the growth of lung metastases but did not cause disease regression. Based 
on the observed effect of PARP inhibition on local MPNST growth in our mouse models, this 
was expected. In our experimental lung metastasis model, treatment begins three weeks after 
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the tail vein injection in order for micrometastases to be present. In this way, we are measuring 
the ability of MPNST cells to establish and proliferate in the lung versus a true metastatic 
cascade. Still, up to 50% of MPNST patients, especially those with NF1, can present with 
metastatic disease at the time of initial diagnosis, therefore this mouse model may be relevant 
to this clinical setting. (7)  
The experimental metastasis model was also used to evaluate survival to determine 
how AZD2281 might benefit MPNST patients with disseminated disease. We treated the 
animals with AZD2281 following the tail vein injection and sacrificed individual mice only when 
signs of disease were present. Approximately 70% (5/7) of animals that received AZD2281 
treatment survived with lung metastases, compared to 0% (0/7) in the control group. These 
results highlight the use of PARP inhibition as a potential MPNST therapeutic strategy to 
manage metastatic lung growths, which could expand the potential application of PARP 
inhibitor treatment. There are several current clinical trials evaluating the effect of PARP 
inhibitor treatment in metastatic disease, including advanced solid tumors and triple negative 
breast cancer; metastatic MPNST patients could therefore be incorporated in this type of trial. 
Furthermore, approximately 20-54% of patients with malignancies, most notably 
osteosarcoma, melanoma, and Ewing’s sarcoma, will develop lung metastases. (121) 
Therefore, PARP inhibitor treatment could be evaluated in these tumors, especially those with 
a characterized DNA repair defect, for potential benefit, not only for the primary lesion, but 
progressive disease to the lung.   
Based on the exciting inhibitory activity of single agent AZD2281 in MPNST, we wanted 
to determine what genetic mutations or dysregulations led to sensitivity to this drug. Several 
mechanisms of sensitivity to AZD2281 have been reported in a variety of disease models; 
specifically, mutations in ATM, BRCA1 and BRCA2, PTEN, RAD51C, and RAD51D. 
(49,116,122-127) All of these genes are involved in the cellular response to DNA damage or 
the repair of double strand DNA breaks. Furthermore, in keratinocytes, PTEN downregulation 
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has been shown to impair GGR, a subpathway of nucleotide excision repair, by suppressing 
the expression of XPC, highlighting the possible links between DNA repair pathways. (128)  
In addition, X. Yang et al. recently showed the sensitivity of a HR-intact pancreatic 
adenocarcinoma cell line, JF-305, to AZD2281, indicating potential mechanisms of cellular 
sensitivity to PARP inhibition beyond HR defects that are yet to be elucidated. (129) To 
determine a potential mechanism of sensitivity of MPNST to AZD2281, we began by 
evaluating the level of HR and NHEJ repair in our cell lines.     
HR and NHEJ efficiency was determined using the eGPF-Pem1 plasmid system which 
requires the transient transfection of a transfection control plasmid, pDs-Red2, and either a 
linearized HR plasmid or linearized NHEJ plasmid. Our results indicate HR repair levels of 
MPNST cell lines are similar MDA-MB-436 cells which have a known HR deficiency. In 
addition, the NHEJ activity of the MPNST cell lines were similar to the control T47D cells with 
proficient NHEJ repair. Therefore, although no specific mutations or dysregulations in HR 
genes have been reported in MPNST, there is decreased HR activity that could contribute to 
the observed MPNST sensitivity to AZD2281. In addition, the increased activity of NHEJ could 
further enhance MPNST sensitivity to PARP inhibition by augmenting chromosomal 
instability.  
It has been shown that treatment of HR-deficient cells with a PARP inhibitor, can 
increase the activity of NHEJ, and due to its error-prone nature, increase the level of genomic 
instability of the cells. (86) To determine if NHEJ has increased activity in MPNST cell lines 
after PARP inhibition, we first treated our cells with AZD2281. We observed stable activation 
of DNA-PKcs, a critical member of NHEJ repair, via immunoblot expression of DNA-PKcs 
Ser2056, and also increased chromosomal aberrations via metaphase spread analysis. 
Ser2056 of DNA-PKcs is an autophosphorylation site that is required for the full activation of 
DNA-PKcs and acts to limit end resection in the cell and therefore promote NHEJ over HR. 
(130-132) To determine if the increased chromosomal damage after AZD2281 treatment was 
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due to increased NHEJ activity, we treated our cells with two combinations of AZD2281 and 
NU7026. Dual treatment decreased the amount of phosphorylated DNA-PKcs expression, 
especially with the highest dose combination, but altered the amount of observed 
chromosomal breaks in a cell line-specific manner. The S462 cell line had the highest level 
of NHEJ as shown by the eGFP-Pem1 plasmid system, therefore perhaps the large observed 
reduction in chromosomal damage after dual treatment could be due to its enhanced 
endogenous NHEJ. For this cell line the sensitivity to PARP inhibition could, in part, be due 
to the increase in NHEJ activity and subsequent genomic instability that results from its error-
prone activity. In addition, the increased/ steady level of chromosomal breaks observed in the 
remaining cell lines after dual treatment could be due to increased chromosomal damage due 
to inhibition of an additional DNA repair pathway, NHEJ. However, perhaps a more substantial 
inhibition of chromosomal damage could have been achieved by pretreating the cells with the 
DNA-PKcs inhibitor, NU7026, prior to AZD2281 treatment. 
To further evaluate DNA repair gene expression in MPNST, we performed RNA 
sequencing of our MPNST cell lines. Due to the sensitivity mechanisms reported, we focused 
the investigation of our RNAseq results to reported DNA repair-related genes. (102) We 
expected to see decreased expression of DNA repair genes that would cause synthetic 
lethality with PARP inhibition, specifically those involved in HR, in our MPNST cell lines 
compared to a NSC control. However, our results indicate the majority of DNA repair-related 
genes were overexpressed in MPNST cell lines, including EXO1, PCNA, RPA3, BRCA1, and 
UNG, which were among the top overexpressed DNA repair-related genes in three out of four 
MPNST cell lines evaluated. This observation corresponds to previous findings that MPNSTs 
have a higher expression of DNA repair genes compared to plexiform neurofibromas, the 
precursor benign lesion of NF1-associated MPNST. (133) This could further indicate an 
increased inherent level of DNA damage in MPNST. However, future experiments will be 
required to determine the status of these genes beyond expression, such as mutation and 
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functional status. Several DNA repair-related genes were downregulated in at least 2 out of 
4 MPNST cell lines (Table 7). These genes include ERCC6, MSH4, PER1, DMC1, and 
ERCC5. MSH4 and DMC1 play essential roles in HR during meiosis. (134,135) Because our 
focus concerns the repair of DNA damage in mitotic cells, no further investigation on the role 
of these genes in AZD2281 sensitivity was performed. PER1 is a clock gene essential for 
circadian rhythm. It has been shown to have decreased expression in human cancers 
including breast, colon, lung, and endometrial cancer, and decreased expression can reduce 
activation of the DNA damage response signal after ionizing radiation. (136) However, these 
results have been inconclusive, with subsequent studies unable to validate an effect of PER1 
on DNA damage response. (137) Finally, ERCC6 (encoding CSB) and ERCC5 are critical to 
DNA damage recognition and repair through the nucleotide excision repair pathway. In the 
event of CSB dysregulation, repair cannot proceed through the transcription coupled repair 
(TCR) subpathway of NER and must proceed through the slower GGR subpathway. 
ERCC5/XPG is an endonuclease in the NER pathway; decreased expression could indicate 
a loss of DNA repair through the GGR subpathway of NER. Taken together, the decreased 
expression of these two genes could indicate a loss of NER activity in MPNST.   
In a previous study to determine mechanisms of sensitivity, aside from HR defects, that 
could cause sensitivity to PARP inhibition, C. Lord et al. performed a high throughput siRNA 
screen using PARP inhibitor-treated breast cancer cells. (69) They found two novel TCR 
genes, XAB2 and DDB1, which sensitized cells to PARP inhibition. Furthermore, they 
hypothesized that a defect in the TCR pathway could result in stalled replication forks, 
eventual collapse of the replication fork, and highly deleterious dsDNA breaks beyond a 
threshold of viability for the cells. Although XAB2 and DDB1 were not specifially differentially 
expressed in MPNST cell lines, this study suggests a TCR deficiency as a mechanism of 
sensitivity to AZD2281. Furthermore, N. Batenburg et al. recently showed that complete 
knockout of CSB decreased the amount of HR and increased the amount of NHEJ compared 
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to parental hTERT-retinal pigment epithelial cells. (76) This result also correlated to sensitivity 
to Olaparib and decreased damage response signaling after IR. This indicates that CSB plays 
a role in facilitating HR repair of DSBs, perhaps by facilitating the recruitment of BRCA1 to 
sites of DNA damage, and that loss of CSB drives S/G2 phase NHEJ activity, increasing 
genomic instability and subsequently sensitivity to PARP inhibition. However, it is important 
to note that this result is shown after complete knockout of CSB, whereas MPNST only shows 
decreased expression of CSB. Due to the possible importance of TCR in PARP inhibitor 
sensitivity, the observed decrease in HR activity, and because ERCC6 was the most 
downregulated DNA repair-related gene found in our MPNST cell panel, we proceeded to 
determine its potential important in MPNST sensitivity to PARP inhibition. 
CSB is a SWI/SNF-like DNA-dependent ATPase, that along with its role in TCR, has 
been reported to play a role in transcriptional elongation at natural transcription pause sites, 
resumption of RNA synthesis after DNA damage, as well as chromatin remodeling, and 
unwinding of the DNA. (62,138,139) Furthermore, a role for CSB in base excision repair has 
been described. (138) Specifically, CSB stimulates either the direct or indirect incision of 7,8-
dihydro-8-oxoguanine (8-oxoG) residues or alters the DNA structure around the lesion for 
better access of other repair proteins during base excision repair. (138,139) CSB interacts 
with PARP1 with and without oxidative stress; however, after oxidative stress, these proteins 
relocate to sites of DNA damage and CSB becomes PARylated. PARylated CSB has 
decreased DNA-dependent ATPase activity, which is not required for its additional activity in 
BER, but may affects its ability to change the structure of DNA necessary for TCR. CSB may 
also act to keep PARP1 in close proximity to the DNA lesion, aiding in quick repair of the 
DNA. Furthermore, it has been shown that in the event of PARP inhibition treatment, CSB 
could act in the TCR pathway to repair oxidative DNA damage that remains in the absence 
of BER. If CSB were non-functional, single strand breaks could be converted to double strand 
breaks at the replication fork. Fittingly, CSB-deficient human fibroblast cells or CSB-null cells 
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were shown to be more sensitive to PARP inhibition than those cells complemented with 
wildtype CSB or express wildtype CSB. (138,139) This supports a role of CSB in TCR and as 
a backup repair mechanism for oxidative DNA damage after PARP inhibition, and shows that 
loss of CSB can further sensitize cells to PARP inhibition. 
To confirm the downregulation of ERCC6 shown via RNAseq, we first performed qRT-
PCR of our MPNST cell lines and NSCs. Consistent with the RNAseq results, ERCC6 was 
downregulated in MPNST cell lines compared to the NSC control. Confirmation of CSB 
expression in a panel of MPNST cell lines and NSCs indicate an average relative CSB 
expression 6 times higher in NSC than MPNST cell lines. This corresponds with the 
decreased level of CSB expression reported in lung cancer and head and neck squamous 
cell carcinoma patients compared to non-cancer controls. (140,141) Decreased CSB 
expression, among other deficient NER genes, was also shown to increase the risk of disease 
in both models. In addition, the AZD2281 EC50 values for MPNST cells treated for 96 hours 
correlate with the observed CSB expression patterns, as assessed by Spearman’s 
correlation. Based on this result, we wanted to manipulate the expression of CSB and 
determine any effect on the cell sensitivity to AZD2281 treatment.  
We anticipate that CSB overexpression would cause the cells to become less sensitive 
to drug treatment. Based on the AZD2281 EC50 results, CSB overexpression had an effect 
on the AZD2281 sensitivity of S462 and ST88 cell lines but no substantial effect on STS26T 
or MPNST724 cells. These results could indicate that STS26T and MPNST724 cell lines have 
additional defects in the NER pathway downstream of CSB, beyond the decreased 
expression of ERCC5 shown in our RNAseq data, so that while overexpression of CSB has 
a mild effect on AZD2281 sensitivity, increase of CSB expression alone is not enough to 
overcome other genetic dysregulation. In a previous study by J. Newman et al., re-expression 
of wild type CSB in CSB-null, hTERT-immortilized human fibroblasts, caused differential 
expression of approximately 150 genes. (139) A subset of the approximately 50 upregulated 
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genes after CSB re-expression had a role in DNA repair and drug resistance which could 
possibly explain the observed resistance to AZD2281 seen after CSB overexpression in 
MPNST. However, M. Caputo et al. report the opposite expression pattern for CSB, with 
increased expression of CSB in bladder, cervical, prostate, and breast cancer cell types 
compared to normal controls. They hypothesized that CSB plays an anti-apoptotic role in 
these cancer cells by re-equilibrating the cell response upon induction of stress, toward cell 
proliferation and survival by counteracting p53 activity. (142) Subsequent inhibition of CSB 
mRNA expression in these cancer models, reduced cell proliferation and increased the 
sensitivity to conventional chemotherapies. ST88 is the only MPNST cell line assessed with 
wild-type p53 expression, therefore the increased resistance to AZD2281 observed after 
increased CSB expression could be due to increased cell robustness through the interaction 
of CSB and p53. In addition, while it is intriguing, we feel the apparent dichotomy of sensitivity 
between NF1-associated cell lines and sporadic cell lines to AZD2281 is out of the scope of 
this thesis. However, future research should be conducted into how the loss of NF1 in S462 
and ST88 cells could contribute to the resistance of these cells to AZD2281 once CSB is 
overexpressed.   
As a proof of principle, we also knocked down the expression of CSB in MDA-MB-231 
cells. This cell line is shown to be relatively resistant to PARP inhibition, therefore we except 
if CSB has any role in the sensitivity of cells to AZD2281, that its decreased expression would 
cause the cells to become sensitive to treatment. We observed a substantial decrease in the 
AZD2281 EC50 of MDA-MB-231 cells with CSB knockdown compared to the control cells. 
This indicates that manipulation of CSB alone is enough to induce PARP inhibitor sensitivity 
in this cell line. In accordance with these results, we wanted to elucidate if manipulation of 
CSB expression would affect the ability of the cells to repair induced UV damage, specifically 
CPDs, by the NER pathway, the most defined role for CSB. 
To assess the effect of CSB overexpression on MPNST cell response to UV damage, 
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we treated the cells with 256J/m2/min UVB and harvested samples 0-24 hours post UV. We 
used the treated DNA for an ELISA to measure the amount of resolved CPDs over time. We 
expected if CSB overexpression could make the cells less sensitive to PARP inhibition, 
potentially by restoring TCR repair of DNA damage, that CSBOE cell lines would be more 
proficient in CPD repair than control cell lines. In addition, to confirm that CPDs were resolved 
and not converted in double strand DNA breaks, we also performed immunoblots of gamma-
H2AX, a marker of DNA double strand breaks, at corresponding time points to the ELISA. 
Our results show no change in CPD resolution or gamma-H2AX accumulation after UV 
damage, regardless of CSB expression level. As previously discussed, CSB has a role in 
chromatin remodeling that allows access to the DNA and a role in RNA polymerase II 
transcription, potentially supporting transcription as well as DNA repair. (62,138,139) 
Therefore, while we expected CSB overexpression or knockdown to effect the efficiency of 
repair of CPD damage, the observed effect of CSB expression on AZD2281 sensitivity could 
be due to a role of CSB outside of NER. In addition, the MTS assays performed that show a 
correlation between CSB expression and AZD2281 sensitivity in a subset of MPNST cell lines 
was performed over 7 days; the CPD ELISA was performed over 24 hours. Therefore, the 
effect of CSB expression of AZD2281 sensitivity could have a temporal aspect that was not 
considered in the CPD ELISA.  
Conclusions and Future Directions 
MPNST is an aggressive malignancy for which effective targeted therapies are 
urgently needed to improve therapeutic options and overall patient survival. In this study, 
we demonstrate that PARP inhibition, specifically AZD2281, exerts a strong anti-MPNST 
effect in vitro and in vivo as a single agent. This effect could be due to deficient DNA repair 
mechanisms, including deficient HR and over-activity of NHEJ, resulting in enhanced 
genomic instability, and possibly by decreased expression of CSB. Our study provides 
evidence that PARP inhibition, specifically with AZD2281, could hold therapeutic benefit for 
84 
 
MPNST patients and warrants a clinical trial. However, patients often develop resistance to 
single agent treatment, therefore future studies should be aimed at determining a 
synergistic drug combination with AZD2281 that could increase efficacy while decreasing 
effective doses and off-target effects. Furthermore, additional PARP inhibitors with a similar 
mechanism of action as AZD2281 are available, further work to evaluate these drugs for 
greater anti-MPNST effects should be done in order to expand potential clinical trial 
applications. Importantly, the effect of long term treatment of an inhibitor of DNA repair, 
such as AZD2281, should be assessed to determine the potential consequence of 
secondary tumorigenesis.     
Future investigations are also necessary to determine the specific genetic mutations 
or modifications in the HR, NHEJ, and NER pathways that contribute to their dysregulation. 
In addition, interrogation of the mechanism of CSB loss could help to expand the potential 
patient population that could benefit from PARP inhibition treatment. As previously 
mentioned, CSB has multiple roles in the cell beyond DNA repair, including chromatin 
remodeling, telomere maintenance, and transcription-associated DNA recombination. (76) 
Determining which roles CSB plays in MPNST will be crucial in elucidating the importance 
of decreased CSB expression observed in MPNST cell lines. Furthermore, our data 
suggests that CSB overexpression in NF1-associated MPNST cells lines has more of an 
effect on the resistance to AZD2281 than in the sporadic cell lines. Examination of this 
phenomenon could further elucidate the link between CSB expression and PARP inhibitor 
sensitivity.  
There are several roadblocks to furthering the field of MPNST research including the 
limited bioresources available. The creation of human tumor cell lines in order to expand 
research data sets would greatly enhance scientific investigation in this field. In addition, 
NF1-associated cell lines do not grow in mouse models, severely limiting the amount of 
research that can be done in this MPNST subtype. Better mouse models for MPNST, in 
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particular NF1-associated MPNST, should be a goal for future research. Furthermore, as 
MPNST cell lines do not spontaneously metastasize in mice, metastatic MPNST research 
is lacking. Due to the aggressive nature of MPNST and the propensity for these tumors to 
metastasize, a mouse model that could better follow the natural order of the disease should 
be a priority for future studies and is imperative to more fully understand the biology of this 
destructive and lethal malignancy.  
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